<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:CURX="http://curanexpharma.com/20260930"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="curx-20260930.xsd" xlink:type="simple"/>
    <context id="From2026-01-01to2026-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-11-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <instant>2026-11-13</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-07-012026-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CURX:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CURX:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CURX:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CURX:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CURX:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CURX:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CURX:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CURX:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CURX:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CURX:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CURX:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CURX:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CURX:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CURX:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2026-07-222026-07-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2026-07-22</startDate>
            <endDate>2026-07-22</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2025-09-122025-09-12_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-12</startDate>
            <endDate>2025-09-12</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-12_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-12</instant>
        </period>
    </context>
    <context id="From2025-01-012025-01-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <instant>2026-09-01</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_VehiclesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_VehiclesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-02-012025-02-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="From2025-05-012025-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="AsOf2025-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="From2025-09-012025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-08-272025-08-27_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-27</startDate>
            <endDate>2025-08-27</endDate>
        </period>
    </context>
    <context id="From2025-09-122025-09-12_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-12</startDate>
            <endDate>2025-09-12</endDate>
        </period>
    </context>
    <context id="From2025-09-232025-09-23_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-23</startDate>
            <endDate>2025-09-23</endDate>
        </period>
    </context>
    <context id="From2026-03-182026-03-18_custom_Dr.HuijuanZhongMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CURX:Dr.HuijuanZhongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-18</startDate>
            <endDate>2026-03-18</endDate>
        </period>
    </context>
    <context id="From2026-07-272026-07-27_custom_Dr.HuijuanZhongMember_custom_TwentyTwentySixPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CURX:Dr.HuijuanZhongMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CURX:TwentyTwentySixPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-27</startDate>
            <endDate>2026-07-27</endDate>
        </period>
    </context>
    <context id="From2026-08-072026-08-07_custom_Dr.HuijuanZhongMember_custom_TwentyTwentySixPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CURX:Dr.HuijuanZhongMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CURX:TwentyTwentySixPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-07</startDate>
            <endDate>2026-08-07</endDate>
        </period>
    </context>
    <context id="From2026-08-202026-08-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2026-08-20</startDate>
            <endDate>2026-08-20</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-14_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-05-312026-05-31_custom_TwoThousandTwentySixEquityIncentivePlanMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CURX:TwoThousandTwentySixEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-31</startDate>
            <endDate>2026-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-05-31_custom_TwoThousandTwentySixEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CURX:TwoThousandTwentySixEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-31</instant>
        </period>
    </context>
    <context id="From2026-06-012026-06-30_custom_TwoThousandTwentySixEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CURX:TwoThousandTwentySixEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-07-21_custom_TwoThousandTwentySixEquityIncentivePlanMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CURX:TwoThousandTwentySixEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-21</instant>
        </period>
    </context>
    <context id="AsOf2026-07-21_custom_TwoThousandTwentySixEquityIncentivePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CURX:TwoThousandTwentySixEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-21</instant>
        </period>
    </context>
    <context id="From2026-07-212026-07-21_custom_TwoThousandTwentySixEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CURX:TwoThousandTwentySixEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-21</startDate>
            <endDate>2026-07-21</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_TwoThousandTwentySixEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CURX:TwoThousandTwentySixEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_TwoThousandTwentySixEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CURX:TwoThousandTwentySixEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-262026-07-26_custom_TwoThousandTwentySixEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CURX:TwoThousandTwentySixEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-26</startDate>
            <endDate>2026-07-26</endDate>
        </period>
    </context>
    <context id="From2026-07-272026-07-27_custom_TwoThousandTwentySixEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CURX:TwoThousandTwentySixEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-27</startDate>
            <endDate>2026-07-27</endDate>
        </period>
    </context>
    <context id="From2026-08-072026-08-07_custom_TwoThousandTwentySixEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CURX:TwoThousandTwentySixEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-07</startDate>
            <endDate>2026-08-07</endDate>
        </period>
    </context>
    <context id="From2026-07-272026-07-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2026-07-27</startDate>
            <endDate>2026-07-27</endDate>
        </period>
    </context>
    <context id="From2026-08-072026-08-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2026-08-07</startDate>
            <endDate>2026-08-07</endDate>
        </period>
    </context>
    <context id="From2026-07-262026-07-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2026-07-26</startDate>
            <endDate>2026-07-26</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_GeneralAndAdministrativeExpense">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_ResearchAndDevelopmentExpense">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_PrepaidExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CURX:PrepaidExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_BusinessDevelopmentServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CURX:BusinessDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_ClinicalFeasibilityServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CURX:ClinicalFeasibilityServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-03-182026-03-18_custom_Dr.HuijuanZhongMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CURX:Dr.HuijuanZhongMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-18</startDate>
            <endDate>2026-03-18</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-18_custom_Dr.HuijuanZhongMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CURX:Dr.HuijuanZhongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-18</instant>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_GeneralAndAdministrativeExpense">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_GeneralAndAdministrativeExpense">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_GeneralAndAdministrativeExpense">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-10-19_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-10-19</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>CURX:Segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2026-01-01to2026-09-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2026-01-01to2026-09-30" id="Fact000004">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2026-01-01to2026-09-30" id="Fact000005">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2026-01-01to2026-09-30" id="Fact000006">0002025942</dei:EntityCentralIndexKey>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2026-09-30"
      id="xdx2ixbrl0073"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0169"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0171"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0231"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0251"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2026-01-012026-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2026-01-012026-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-07-012026-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <CURX:PaymentOfUnderwritingOfferingCosts
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="AsOf2026-09-30"
      id="xdx2ixbrl0528"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedRentCurrent
      contextRef="AsOf2026-09-30"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="AsOf2026-09-30"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0602"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0628"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0629"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0631"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0632"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0634"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0635"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0640"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0641"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0643"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0644"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0646"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0647"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0649"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0650"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0655"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0656"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0658"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0659"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0661"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0662"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0667"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0668"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0670"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0671"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0673"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0674"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0676"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0677"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0689"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0691"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0693"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0695"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0697"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0699"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0701"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0703"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0713"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0715"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0717"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0719"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0729"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0731"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0733"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0735"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0737"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0739"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0741"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0743"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0753"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0755"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0757"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0759"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsOtherTaxCarryforwards
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0767"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2026-09-30"
      id="xdx2ixbrl0775"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0776"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2026-07-012026-09-30_us-gaap_GeneralAndAdministrativeExpense"
      id="xdx2ixbrl0916"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_us-gaap_GeneralAndAdministrativeExpense"
      id="xdx2ixbrl0920"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30_us-gaap_GeneralAndAdministrativeExpense"
      id="xdx2ixbrl0922"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2026-01-01to2026-09-30" id="Fact000014">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2026-01-01to2026-09-30" id="Fact000015">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2026-01-01to2026-09-30" id="Fact000016">2026-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2026-01-01to2026-09-30" id="Fact000017">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2026-01-01to2026-09-30" id="Fact000018">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2026-01-01to2026-09-30" id="Fact000019">001-42815</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2026-01-01to2026-09-30" id="Fact000020">Curanex Pharmaceuticals Inc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2026-01-01to2026-09-30" id="Fact000021">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2026-01-01to2026-09-30" id="Fact000022">83-0741390</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2026-01-01to2026-09-30" id="Fact000023">2 Jericho     Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2026-01-01to2026-09-30" id="Fact000024">Suite 101B</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2026-01-01to2026-09-30" id="Fact000025">Jericho</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2026-01-01to2026-09-30" id="Fact000026">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2026-01-01to2026-09-30" id="Fact000027">11753</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2026-01-01to2026-09-30" id="Fact000028">(718)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2026-01-01to2026-09-30" id="Fact000029">673-6078</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2026-01-01to2026-09-30" id="Fact000030">Common Stock, par value     $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2026-01-01to2026-09-30" id="Fact000031">CURX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2026-01-01to2026-09-30" id="Fact000032">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2026-01-01to2026-09-30" id="Fact000033">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2026-01-01to2026-09-30" id="Fact000034">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2026-01-01to2026-09-30" id="Fact000035">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2026-01-01to2026-09-30" id="Fact000036">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2026-01-01to2026-09-30" id="Fact000037">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2026-01-01to2026-09-30" id="Fact000038">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="From2026-01-01to2026-09-30" id="Fact000039">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-11-13"
      decimals="INF"
      id="Fact000040"
      unitRef="Shares">1568216</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityListingParValuePerShare
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000041"
      unitRef="USDPShares">0.0001</dei:EntityListingParValuePerShare>
    <us-gaap:Cash
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000049"
      unitRef="USD">1579689</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000050"
      unitRef="USD">4973134</us-gaap:Cash>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000052"
      unitRef="USD">976701</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000053"
      unitRef="USD">6254374</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000055"
      unitRef="USD">2556390</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000056"
      unitRef="USD">11227508</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000058"
      unitRef="USD">540622</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000059"
      unitRef="USD">352616</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000061"
      unitRef="USD">3097012</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000062"
      unitRef="USD">11580124</us-gaap:Assets>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000070"
      unitRef="USD">9741</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">11915</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">2426</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000076"
      unitRef="USD">133559</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">122689</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000079"
      unitRef="USD">143300</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">137030</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000082"
      unitRef="USD">408531</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000083"
      unitRef="USD">224010</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000085"
      unitRef="USD">551831</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">361040</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000094"
      unitRef="Shares">475000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000096"
      unitRef="Shares">475000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000098"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000100"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000102"
      unitRef="Shares">1568241</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000104"
      unitRef="Shares">1568241</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000106"
      unitRef="Shares">1417041</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000108"
      unitRef="Shares">1417041</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000091"
      unitRef="USD">157</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000092"
      unitRef="USD">142</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000113"
      unitRef="Shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000115"
      unitRef="Shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000117"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000119"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000121"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000123"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000125"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000127"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000110"
      unitRef="USD">100</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000111"
      unitRef="USD">100</us-gaap:PreferredStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000129"
      unitRef="USD">16649274</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000130"
      unitRef="USD">16066397</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000132"
      unitRef="USD">-14104350</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000133"
      unitRef="USD">-4847555</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000135"
      unitRef="USD">2545181</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000136"
      unitRef="USD">11219084</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000138"
      unitRef="USD">3097012</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000139"
      unitRef="USD">11580124</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2026-01-01to2026-09-30" id="Fact000142">1-for-20</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000149"
      unitRef="USD">877121</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000150"
      unitRef="USD">273853</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000151"
      unitRef="USD">2536161</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000152"
      unitRef="USD">466863</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000154"
      unitRef="USD">1952587</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000155"
      unitRef="USD">677474</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000156"
      unitRef="USD">6802466</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000157"
      unitRef="USD">679574</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000159"
      unitRef="USD">2829708</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000160"
      unitRef="USD">951327</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000161"
      unitRef="USD">9338627</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000162"
      unitRef="USD">1146437</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000164"
      unitRef="USD">-2829708</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000165"
      unitRef="USD">-951327</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000166"
      unitRef="USD">-9338627</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000167"
      unitRef="USD">-1146437</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000170"
      unitRef="USD">4090</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000172"
      unitRef="USD">8537</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000174"
      unitRef="USD">14111</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000175"
      unitRef="USD">1358</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000176"
      unitRef="USD">81832</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000177"
      unitRef="USD">2986</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000179"
      unitRef="USD">-2815597</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000180"
      unitRef="USD">-954059</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000181"
      unitRef="USD">-9256795</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000182"
      unitRef="USD">-1151988</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact000184"
      unitRef="USDPShares">-1.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact000186"
      unitRef="USDPShares">-1.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000188"
      unitRef="USDPShares">-0.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000190"
      unitRef="USDPShares">-0.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000192"
      unitRef="USDPShares">-6.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000194"
      unitRef="USDPShares">-6.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact000196"
      unitRef="USDPShares">-0.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact000198"
      unitRef="USDPShares">-0.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact000200"
      unitRef="Shares">1516284</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact000202"
      unitRef="Shares">1516284</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000204"
      unitRef="Shares">1279984</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000206"
      unitRef="Shares">1279984</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000208"
      unitRef="Shares">1450951</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000210"
      unitRef="Shares">1450951</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact000212"
      unitRef="Shares">1226954</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact000214"
      unitRef="Shares">1226954</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2026-01-01to2026-09-30" id="Fact000217">1-for-20</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000226"
      unitRef="Shares">1200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000219"
      unitRef="USD">120</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000228"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000220"
      unitRef="USD">100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_custom_CommonStockToBeIssuedMember"
      decimals="0"
      id="Fact000221"
      unitRef="USD">200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000222"
      unitRef="USD">925589</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000223"
      unitRef="USD">-622449</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000224"
      unitRef="USD">503360</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000234"
      unitRef="USD">-137583</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000235"
      unitRef="USD">-137583</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000244"
      unitRef="Shares">1200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000237"
      unitRef="USD">120</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000246"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000238"
      unitRef="USD">100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_CommonStockToBeIssuedMember"
      decimals="0"
      id="Fact000239"
      unitRef="USD">200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000240"
      unitRef="USD">925589</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000241"
      unitRef="USD">-760032</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000242"
      unitRef="USD">365777</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000252"
      unitRef="USD">-60346</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000253"
      unitRef="USD">-60346</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000262"
      unitRef="Shares">1200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000255"
      unitRef="USD">120</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000264"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000256"
      unitRef="USD">100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_custom_CommonStockToBeIssuedMember"
      decimals="0"
      id="Fact000257"
      unitRef="USD">200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000258"
      unitRef="USD">925589</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000259"
      unitRef="USD">-820378</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000260"
      unitRef="USD">305431</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000273"
      unitRef="Shares">217041</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000266"
      unitRef="USD">22</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_custom_CommonStockToBeIssuedMember"
      decimals="0"
      id="Fact000268"
      unitRef="USD">-200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000269"
      unitRef="USD">15140808</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000271"
      unitRef="USD">14940831</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000279"
      unitRef="USD">-954059</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000280"
      unitRef="USD">-954059</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000289"
      unitRef="Shares">1417041</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000282"
      unitRef="USD">142</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000291"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000283"
      unitRef="USD">100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000285"
      unitRef="USD">16066397</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000286"
      unitRef="USD">-1774437</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000287"
      unitRef="USD">14292202</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000300"
      unitRef="Shares">1417041</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000293"
      unitRef="USD">142</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000302"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000294"
      unitRef="USD">100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000296"
      unitRef="USD">16066397</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000297"
      unitRef="USD">-4847555</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000298"
      unitRef="USD">11219084</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000311"
      unitRef="Shares">1200</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000307"
      unitRef="USD">9792</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000309"
      unitRef="USD">9792</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000317"
      unitRef="USD">-3150228</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000318"
      unitRef="USD">-3150228</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000327"
      unitRef="Shares">1418241</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000320"
      unitRef="USD">142</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000329"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000321"
      unitRef="USD">100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000323"
      unitRef="USD">16076189</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000324"
      unitRef="USD">-7997783</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000325"
      unitRef="USD">8078648</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000335"
      unitRef="USD">-3290970</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000336"
      unitRef="USD">-3290970</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000345"
      unitRef="Shares">1418241</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000338"
      unitRef="USD">142</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-06-30_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000347"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000339"
      unitRef="USD">100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000341"
      unitRef="USD">16076189</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000342"
      unitRef="USD">-11288753</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000343"
      unitRef="USD">4787678</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000356"
      unitRef="Shares">150000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000349"
      unitRef="USD">15</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000352"
      unitRef="USD">573085</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000354"
      unitRef="USD">573100</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000362"
      unitRef="USD">-2815597</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000363"
      unitRef="USD">-2815597</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000372"
      unitRef="Shares">1568241</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000365"
      unitRef="USD">157</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000374"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000366"
      unitRef="USD">100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000368"
      unitRef="USD">16649274</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000369"
      unitRef="USD">-14104350</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000370"
      unitRef="USD">2545181</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2026-01-01to2026-09-30" id="Fact000377">1-for-20</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000382"
      unitRef="USD">-9256795</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000383"
      unitRef="USD">-1151988</us-gaap:NetIncomeLoss>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000388"
      unitRef="USD">107552</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000389"
      unitRef="USD">45102</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000391"
      unitRef="USD">163801</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000397"
      unitRef="USD">-5696764</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000398"
      unitRef="USD">8586042</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000400"
      unitRef="USD">-100167</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000401"
      unitRef="USD">-44350</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000403"
      unitRef="USD">-2426</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000404"
      unitRef="USD">109489</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000409"
      unitRef="USD">-2174</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000410"
      unitRef="USD">741</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000412"
      unitRef="USD">-3393445</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000413"
      unitRef="USD">-9627048</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000419"
      unitRef="USD">15655192</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <CURX:PaymentOfUnderwritingOfferingCosts
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000422"
      unitRef="USD">346497</CURX:PaymentOfUnderwritingOfferingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000425"
      unitRef="USD">15308695</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000427"
      unitRef="USD">-3393445</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000428"
      unitRef="USD">5681646</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000430"
      unitRef="USD">4973134</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000431"
      unitRef="USD">148891</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000433"
      unitRef="USD">1579689</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000434"
      unitRef="USD">5830537</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <CURX:RecognitionOfRightofuseAssetInExchangeForLeaseLiability
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000439"
      unitRef="USD">295558</CURX:RecognitionOfRightofuseAssetInExchangeForLeaseLiability>
    <CURX:RecognitionOfRightofuseAssetInExchangeForLeaseLiability
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000440"
      unitRef="USD">105501</CURX:RecognitionOfRightofuseAssetInExchangeForLeaseLiability>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000442">&lt;p id="xdx_806_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zypzOCjq7SNj" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_828_zL015E5tv755"&gt;Description of Business and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zNk5sU6qiVPh"&gt;Description
of Business&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Curanex
Pharmaceuticals Inc (the &#x201c;Company&#x201d;) was originally incorporated as Durand Damiel Health Inc. under the laws of the State
of New York on June 1, 2018. The Company is headquartered in Jericho, NY, with an initial focus on research and development of health
products and botanical medicines.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 9, 2023, the Company was rebranded as Curanex Pharmaceuticals Inc, and shifted its focus to discovering, developing, and commercializing
innovative botanical drugs for treating major unmet medical needs in patients with inflammatory diseases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 10, 2024, Curanex Pharmaceuticals Inc., a New York corporation (&#x201c;Curanex NY&#x201d;), entered into an Agreement and Plan of
Merger (the &#x201c;Merger Agreement&#x201d;) with Curanex Pharmaceuticals Inc, (the &#x201c;Surviving Corporation&#x201d;), a newly formed
Nevada corporation and wholly owned subsidiary of Curanex NY. Pursuant to the Merger Agreement, on the same date, Curanex NY, as the
parent in this transaction, merged with and into the Surviving Corporation (the &#x201c;Reincorporation Merger&#x201d;). Upon the consummation
of the Reincorporation Merger, Curanex NY ceased its legal existence as a New York corporation, and the Surviving Corporation continued
the business as the surviving corporation under the name &#x201c;Curanex Pharmaceuticals Inc&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements for the year ended 2024 reflect the impact of the Reincorporation Merger. In accordance with ASC 805 Business Combinations,
the merger has been treated as a reorganization under common control. As such, the assets and liabilities have been transferred to the
Surviving Corporation at their historical carrying amounts, and no gain or loss has been recognized in connection with the merger. The
balance sheet now presents the Nevada corporation as the surviving entity, incorporating the combined assets and liabilities of the predecessor
and the successor entities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
merger did not result in any changes to the reported financial position or results of operations for prior periods, as the historical
financial information of the Company has been carried forward to the Surviving Corporation. The impact of the merger on the financial
statements is primarily legal and administrative, ensuring the continuity of the Company&#x2019;s operations under the new jurisdiction
without interruption. Consequently, the financial statements include all transactions and balances of both the original and the surviving
entities, presented as if the merger had occurred at the beginning of the earliest period presented. This approach ensures consistency
and comparability in the financial reporting of the Company&#x2019;s ongoing business activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 27, 2025, the Company successfully completed its initial public offering (the &#x201c;IPO&#x201d;) and began trading on the Nasdaq
Capital Market under the ticker symbol &#x201c;CURX.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the completion of our IPO, the Company incurred significant research and development (&#x201c;R&amp;amp;D&#x201d;) expense, totaling approximately
$&lt;span id="xdx_90C_eus-gaap--OtherResearchAndDevelopmentExpense_c20250101__20251231_zUVGvWDVcRMa" title="Research and development expense"&gt;2,983,773&lt;/span&gt; within the year ended December 31, 2025. These expenditures primarily related to FDA-mandated investigational new drug (&#x201c;IND&#x201d;)-enabling
studies supporting programs in ulcerative colitis, atopic dermatitis, rheumatoid arthritis, gouty arthritis, and diabetic foot. R&amp;amp;D
activities during the period included good laboratory practice (&#x201c;GLP&#x201d;) toxicology and pharmacokinetic/bioanalytical studies,
chemistry, manufacturing, and controls (&#x201c;CMC&#x201d;) work involving formulation, stability, and method validation, as well as fees
to Contract Research Organizations (&#x201c;CROs&#x201d;) and Contract Development and Manufacturing Organizations (&#x201c;CDMOs&#x201d;).
The increase in R&amp;amp;D expense compared to prior periods reflects the progression of multiple investigational programs through preclinical
development toward IND submission and future clinical evaluation, consistent with the Company&#x2019;s development strategy following
the IPO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2026, the Company expanded its drug development pipeline by adding oncology as a new core therapeutic area, supplementing its existing
six core therapeutic areas. Patients with advanced or relapsed cancers often have limited treatment alternatives, representing substantial
unmet medical needs and considerable long-term commercial potential. While continuing to advance its lead preclinical candidate Phyto-N
and other pipeline assets targeting inflammatory and metabolic diseases, the Company&#x2019;s strategic expansion into oncology further
diversifies its product portfolio, aligns with its long-term therapeutic development focus, and strengthens its overall positioning as
an emerging biotechnology company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 22, 2026, the Board approved, by unanimous written consent, &lt;span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20260722__20260722_z4XosL86Z022" title="Reverse stock split, description"&gt;a 1-for-20 Reverse Stock Split of the Company&#x2019;s issued and outstanding
common stock, which became effective on August 20, 2026. At the effective time, every 20 shares of common stock were automatically converted
into one share, with fractional shares rounded up to the nearest whole share. The Reverse Stock Split was effected to regain compliance
with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq.&lt;/span&gt; All share and per-share
amounts in these unaudited financial statements have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zp3T5pTMGps9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zBYIuU3WOfC"&gt;Basis
of Accounting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying financial statements of the Company have been prepared on the accrual basis of accounting in accordance with Generally Accepted
Accounting Principles in the United States of America (GAAP).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zLf7a1TZQL07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zNa2n2CZnM95"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the Company&#x2019;s unaudited interim financial statements in conformity with accounting principles generally accepted
in the United States of America (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses
during the reporting periods. Significant estimates and assumptions reflected in these interim financial statements are consistent with
those described in the Company&#x2019;s most recent annual financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
estimates and assumptions are based on historical experience and other factors that management believes are reasonable under the circumstances.
Due to the inherent uncertainty involved in making estimates, actual results could differ from those estimates, and such differences
may be material to the financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
evaluates its estimates on an ongoing basis. Changes in estimates are recognized in the period in which they become known and, if applicable,
in future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--GoingConcernPolicyTextBlock_zkPlabuTHMY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zOwEfqEFDvGg"&gt;Going
Concern&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the end of each reporting period, management exercises judgment in assessing the Company&#x2019;s ability to continue as a going concern
in accordance with ASC 205-40, Presentation of Financial Statements&#x2014;Going Concern, by reviewing the Company&#x2019;s performance,
resources, and future obligations. This assessment considers conditions and events that are known and reasonably knowable as of the date
the financial statements are issued and involves critical judgments regarding the Company&#x2019;s short and long-term operating budgets,
expected profitability, investment and financing activities, and strategic planning.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did not generate operating revenue during the recent several years and has incurred recurring net losses and negative cash flows
from operations. For the nine months ended September 30, 2026, the Company incurred a net loss of $&lt;span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_di_c20260101__20260930_zmvaLj5pX2Xc" title="Net loss"&gt;9,256,795&lt;/span&gt; and used cash in operating
activities of approximately $&lt;span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn4n6_di_c20260101__20260930_zHyBc9hZjIGe" title="Cas in operating activities"&gt;3.39&lt;/span&gt; million. As of September 30, 2026, the Company had cash and cash equivalents of $&lt;span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20260930_zbGUCJwBDei7" title="Cash and cash equivalents"&gt;1,579,689&lt;/span&gt; and an accumulated
deficit of $&lt;span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20260930_z5qErkuiWc09" title="Accumulated deficit"&gt;14,104,350&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operating expenses for the nine months ended September 30, 2026 were partially funded through the utilization of prepaid
research and development balances, which declined from $&lt;span id="xdx_901_eus-gaap--OtherPrepaidExpenseCurrent_iI_c20251231_zIzSnMnPuWRi" title="Prepaid research and development"&gt;6,166,294&lt;/span&gt; as of December 31, 2025 to $&lt;span id="xdx_903_eus-gaap--OtherPrepaidExpenseCurrent_iI_c20260930_zlVOvhLPzke9" title="Prepaid research and development"&gt;314,783&lt;/span&gt; as of September 30, 2026. As these
prepaid balances are consumed, the Company expects its cash used in operating activities to increase materially. The Company further
expects research and development expenditures to increase in connection with its planned Investigational New Drug application submission
and subsequent clinical trial activities. The September 30, 2026 prepaid R&amp;amp;D balance includes $&lt;span id="xdx_90E_ecustom--PrepaidExpenseResearchAndDevelopmentCurrent_iI_c20260930_zuvBLvifRiak" title="Prepaid R&amp;amp;D balance"&gt;265,682&lt;/span&gt; of noncash consulting service
prepayments for Australian clinical trial feasibility activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on its current operating plan, the Company does not expect its existing cash and cash equivalents to be sufficient to fund operations
for at least twelve months from the date these unaudited interim financial statements are issued. These conditions raise substantial
doubt about the Company&#x2019;s ability to continue as a going concern. Management&#x2019;s plans to address these conditions include
raising additional capital through the issuance of equity or debt securities, pursuing strategic collaborations or out-licensing arrangements
for its product candidates, and reducing or deferring discretionary operating and development expenditures. There can be no assurance
that the Company will be able to obtain additional financing on acceptable terms, or at all. The Company regained compliance with the
Nasdaq minimum bid price requirement on September 3, 2026; its ability to obtain additional financing remains uncertain. Because these
plans are not considered probable of being effectively implemented within the meaning of ASC 205-40, they do not alleviate the substantial
doubt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited interim financial statements have been prepared assuming the Company will continue as a going concern and do not
include any adjustments to the carrying amounts or classification of assets and liabilities that might result from the outcome of this
uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9jcJQbcdAH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zFpdRgWmVJdj"&gt;Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains balances with multiple financial institutions, with balances periodically exceeding the Federal Deposit Insurance Corporation
(FDIC) insurance limit of $&lt;span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20260930_z2o8kYehkB71" title="FDIC insured amount"&gt;250,000&lt;/span&gt; per depositor, per insured bank, for each account ownership category. The management monitors the
cash balances in the operating accounts and adjusts the cash balances as appropriate; however, these cash balances could be impacted
if the underlying financial institutions fail or are subject to other adverse conditions in the financial markets. To date, the Company
has experienced no loss or lack of access to cash in the operating accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z9uCqixWIfE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zFfvO6uUOaT1"&gt;Basic
and Diluted Net Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company computes loss per share in accordance with ASC 260, Earnings per Share, which requires presentation of both basic and diluted
earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common
shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all
dilutive potential common shares outstanding during the period. During the nine months ended September 30, 2026, and 2025, the Company
had no potential dilutive instruments and accordingly basic loss and diluted loss per share are the same.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--InitialPublicOfferinPolicyTextBlock_zRvWH4gr33S8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zstLZw0sdc8f"&gt;Initial
Public Offering&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company completed its IPO of &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zMAYv1sPgS8" title="Number of shares issued, shares"&gt;187,500&lt;/span&gt; shares of its common stock, par value $&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zbeMdkdIuxv3" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share, at a public offering price of $&lt;span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20260930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z4KsVQctkpOj" title="Sale of stock price per share"&gt;80.00&lt;/span&gt; per
share. This offering generated gross proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20260101__20260930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zZofOuf3CVZ1" title="Gross proceeds"&gt;15.0&lt;/span&gt; million before underwriting discounts, commissions, and other offering expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the IPO, total offering costs were approximately $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn4n6_c20260101__20260930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z45ZqwhPlGB" title="Net proceeds"&gt;2.12&lt;/span&gt; million, consisting of $&lt;span id="xdx_90E_ecustom--UnderwritingDiscountsAndCommissions_pn4n6_c20260101__20260930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zfaZznOQXrL1" title="Underwriting discounts and commissions"&gt;1.41&lt;/span&gt; million in underwriting discounts
and commissions and $&lt;span id="xdx_90B_ecustom--OtherOfferingRelatedExpenses_iI_pn4n6_c20260930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zbPMU4lYhmAe" title="Other offering related expenses"&gt;0.71&lt;/span&gt; million of other offering-related expenses (including legal, accounting, and filing fees). The Company had
previously recorded these other offering costs as deferred IPO costs prior to the effectiveness of the registration statement. Upon the
closing of the IPO, all deferred costs were reclassified and recorded as a reduction to additional paid-in capital (&#x201c;APIC&#x201d;)
within stockholders&#x2019; equity. After deducting total underwriting discounts, commissions, and offering expenses, the Company received
net cash proceeds of approximately $&lt;span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn4n6_c20260101__20260930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zhcrlVZYR8l5" title="Net proceeds"&gt;13.24&lt;/span&gt; million from its IPO. Certain offering costs had been paid by the Company prior to the completion
of the IPO and were recorded as deferred offering costs on the balance sheets prior to being reclassified against additional
paid-in capital upon the consummation of the IPO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--OverAllotmentOptionPolicyTextBlock_zJdxzidglPze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zRjZmg9juQKe"&gt;Over-Allotment
Option&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 12, 2025, the underwriters exercised their option to purchase an additional &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250912__20250912__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zlFEjEsJgSkh" title="Number of shares issued, shares"&gt;28,125&lt;/span&gt; shares of the Company&#x2019;s common
stock at the same public offering price of $&lt;span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250912__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_ztW6h6NJgWN1" title="Sale of stock price per share"&gt;80.00&lt;/span&gt; per share, resulting in gross proceeds of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn4n6_c20250912__20250912__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zMEbJv27eOZ6" title="Gross proceeds"&gt;2.25&lt;/span&gt; million. The Company incurred
$&lt;span id="xdx_904_ecustom--UnderwritingDiscountsAndCommissions_pn4n6_c20250912__20250912__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zQ7k4hBkMkm8" title="Underwriting discounts and commissions"&gt;0.18&lt;/span&gt; million in underwriting discounts and commissions related to the option exercise. After deducting these offering costs, the
Company received net proceeds of $&lt;span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn4n6_c20250912__20250912__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zCwATVtXKDff" title="Net proceeds"&gt;2.07&lt;/span&gt; million. All costs directly attributable to the over-allotment exercise were likewise
recorded as a reduction of APIC within stockholders&#x2019; equity, consistent with the accounting for the initial
closing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zlXgNSXLhvz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zmPAyu7kCsVg"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
820 Fair Value Measurements and Disclosures establishes a framework for all fair value measurements and expands disclosures related to
fair value measurement and developments. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer
a liability in an orderly transaction between market participants at the measurement date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
820 requires that assets and liabilities measured at fair value are classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 &#x2013;
    Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 &#x2013; Inputs
    other than quoted prices that are observable for the asset or liability either directly or indirectly; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 &#x2013; Inputs
    that are not based on observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of cash and accrued liabilities approximate fair value because of the short-term nature of these items.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_zOvJizUtYjv" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zymEQDna1Ho3"&gt;Leases
&amp;amp; Right of Use Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted ASC 842 Leases on January 1, 2022. At inception of a contract, the Company assesses whether a contract is, or contains,
a lease. Contracts that convey the right to control the use of an identified asset for a period of time in exchange for consideration
are accounted for as leases giving rise to right-of-use assets. At the commencement date, a right-of-use asset is measured at cost, where
cost comprises: (a) the amount of the initial measurement of the lease liability; (b) any lease payments made at or before the commencement
date, less any lease incentives received; (c) any initial direct costs incurred by the Company; and (d) an estimate of costs to be incurred
by the Company in dismantling and removing the underlying asset, restoring the site on which it is located or restoring the underlying
asset to the condition required by the terms and conditions of the lease, unless those costs are incurred to produce inventories.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
lease liability is initially measured at the present value of the unpaid lease payments. Subsequently, the Company measures a lease liability
by: (a) increasing the carrying amount to reflect interest on the lease liability; (b) reducing the carrying amount to reflect the lease
payments made; and (c) re-measuring the carrying amount to reflect any reassessment or lease modifications, or to reflect revised in-substance
fixed lease payments. Each lease payment is allocated between repayment of the lease principal and interest. Interest on the lease liability
in each period during the lease term is allocated to produce a constant periodic rate of interest on the remaining balance of the lease
liability. Except where the costs are included in the carrying amount of another asset, the Company recognizes in profit or loss (a)
the interest on a lease liability and (b) variable lease payments not included in the measurement of a lease liability in the period
in which the event or condition that triggers those payments occurs. The Company subsequently measures a right-of-use asset at cost less
any accumulated amortization and any accumulated impairment losses; and adjusted for any re-measurement of the lease liability. Right-of-use
assets are depreciated over the shorter of the asset&#x2019;s useful life and the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_z0jjtmjCokB4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zelh8N631bAa"&gt;Research
and Development Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for research and development (&#x201c;R&amp;amp;D&#x201d;) costs in accordance with ASC 730, Research and Development. R&amp;amp;D
costs are expensed as incurred unless they represent nonrefundable advance payments for goods or services to be received in the future.
Nonrefundable advance payments to third parties&#x2014;such as Contract Research Organizations (&#x201c;CROs&#x201d;), Contract Development
and Manufacturing Organizations (&#x201c;CDMOs&#x201d;), clinical sites, and other service providers&#x2014;are recorded as prepaid expenses
and recognized in R&amp;amp;D expense as the related services are performed, generally over the contractual period of performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;R&amp;amp;D
expense primarily includes employee-related costs (salaries, benefits, and stock-based compensation) for personnel engaged in R&amp;amp;D;
fees to CROs, CDMOs, consultants, and other third parties; clinical trial and preclinical study costs; and costs to manufacture and test
preclinical and clinical materials. The Company records accruals for services performed but not yet invoiced based on estimates of work
completed, patient enrollment/visits, manufacturing progress, and data from vendors. Up-front set-up or activation fees under executory
service arrangements are deferred and recognized over the expected period of performance. Materials, equipment, and licenses with no
alternative future use are expensed when incurred; items with alternative future use are capitalized and recognized in accordance with
the applicable guidance. Prepaid R&amp;amp;D balances are evaluated for recoverability and adjusted for changes in project scope, timing,
or cancellations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zUzdvfV8KmFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z4N2u5YG5C5j"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based compensation in accordance with ASC 718, Compensation&#x2014;Stock Compensation. Share-based payment
awards granted to employees, non-employee directors and non-employee service providers are measured at the grant-date fair value of the
award and recognized as compensation expense over the requisite service period, which is generally the vesting period. Employee awards
that are fully vested on the grant date are expensed in full at that date. For nonemployee awards, the corresponding cost is recognized
as an immediate expense or a prepaid asset based on the goods or services acquired and the enforceable rights conveyed by the arrangement.
The fair value of awards of common stock and restricted stock is determined by reference to the closing price of the Company&#x2019;s
common stock as reported on Nasdaq on the grant date. The fair value of stock options, if granted, is estimated using the Black-Scholes
option-pricing model, which requires management to make assumptions regarding the expected term, expected volatility, risk-free interest
rate and expected dividend yield. Because the Company has limited trading history, expected volatility is estimated by reference to the
historical volatility of a group of comparable publicly traded companies. The Company has elected to account for forfeitures as they
occur. Stock-based compensation expense is classified within research and development expense or general and administrative expense based
on the function of the recipient&#x2019;s services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
fully vested nonemployee consulting shares issued during the third quarter of 2026 in exchange for enforceable rights to future services,
the Company recognizes prepaid services at grant-date fair value and recognizes the related expense as services are received over the
contractual service periods. Immediate vesting of the shares does not accelerate recognition of services not yet received.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zES7fJeR0lB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z6wkQ4f10mhl"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes under ASC 740, Income Taxes. This standard requires the Company to use the asset and liability method,
which involves making estimates and assumptions and exercising judgment regarding the carrying values of assets and liabilities. These
values are subject to inherent accounting estimates, the interpretation of income tax legislation across various jurisdictions, expectations
about future operating results, the timing of reversal of temporary differences, and potential audits of income tax filings by tax authorities.
Deferred tax assets and liabilities are recognized for the future tax consequences of differences between the financial statement carrying
amounts of existing assets and liabilities and their respective tax bases. These assets and liabilities are measured using enacted tax
rates expected to apply to taxable income in the years when those temporary differences are expected to be recovered or settled. The
impact of changes in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment
date. Valuation allowances are established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
the Company incurs losses for income tax purposes, it assesses the probability of future taxable income based on budgeted forecasts.
These forecasts are adjusted to account for non-taxable income and expenses and specific rules on the use of unused credits and tax losses.
If the forecasts indicate that sufficient future taxable income will not be available to deduct the temporary differences, a deferred
tax asset is not recognized for all deductible temporary differences.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--RelatedPartyTransactionsPolicyTextBlock_zNPjgo4uLI1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zS9BiIQqMkNi"&gt;Related
Party Transactions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company identifies and accounts for related party transactions, disclosing them in accordance with ASC 850, Related Party Disclosures,
and other relevant ASC standards. Parties are considered related to the Company if they, directly or indirectly, through one or more
intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include the principal
owners of the Company, its management, members of the immediate families of the principal owners and management, and other parties with
which the Company may engage in transactions if one party controls or can significantly influence the management or operating policies
of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zavHd2VeqH42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zEP87z6R8M4j"&gt;Segment
Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision
maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources and in assessing performance. The Company&#x2019;s Chief Executive Officer
is its CODM. The Company&#x2019;s CODM uses GAAP financial statements for the purposes of making operating decisions, allocating resources
and evaluating financial performance. As such, the Company has determined that it operates in &lt;span id="xdx_90C_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20260101__20260930_zpIsQorWPKc3" title="Number of operating segment"&gt;one&lt;/span&gt; operating and &lt;span id="xdx_90A_eus-gaap--NumberOfReportableSegments_pid_dc_uSegment_c20260101__20260930_zgeBUlBL0Rvl" title="Number of reportable segment"&gt;one&lt;/span&gt; reportable segment.
The Company&#x2019;s long-lived assets are entirely based in the United States.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zy26HT8vnM93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zJoUWDXIdmG4"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is classified as an &#x201c;emerging growth company&#x201d; (EGC) under the Jumpstart Our Business Startups Act of 2012 (the JOBS
Act). This classification allows EGCs to delay adopting new or revised accounting standards issued after the enactment of the JOBS Act
until these standards apply to private companies. The Company has chosen to delay the adoption of these new or revised accounting standards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is classified as a &#x201c;smaller reporting company&#x201d; (SRC) under the Securities and Exchange Commission (SEC) regulations.
This classification allows SRCs to provide scaled disclosures in their SEC filings, including reduced financial statement and executive
compensation disclosure requirements. The Company has elected to take advantage of these scaled disclosure requirements to simplify its
reporting processes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluated the impact of ASU 2024-03, &lt;i&gt;Disaggregation of Income Statement Expenses&lt;/i&gt;, issued by the Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) in November 2024. The update requires additional disclosures to provide disaggregated
information about certain expense captions presented in the income statement, including, among other items, inventory, employee compensation,
depreciation, and amortization, to enhance transparency into the nature of expenses. The amendments in ASU 2024-03 are effective for
annual reporting periods beginning after December 15, 2026, and interim periods thereafter, with early adoption permitted. The Company
is currently evaluating the impact that the adoption of this standard will have on its financial statement disclosures. While the standard
is not expected to have an impact on the Company&#x2019;s results of operations, financial position, or cash flows, it is expected to
result in expanded disclosures upon adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No.
2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#x2019;s
effective tax rate reconciliation as well as additional information on income taxes paid. The Company adopted this ASU on a prospective
basis effective January 1, 2025. Refer to Note 5, Income Taxes for the inclusion of new disclosures required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. The amendments consolidate interim
disclosure requirements and clarify the information to be provided about material developments since the last annual reporting period.
They are effective for interim periods within annual periods beginning after December 15, 2027 for public business entities and after
December 15, 2028 for other entities, with early adoption permitted. The Company is evaluating the disclosure effects and the application
of its emerging growth company extended-transition election.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Apart
from as mentioned above, management does not believe that other recently issued but not yet effective accounting standards, if currently
adopted, would have a material effect on the Company&#x2019;s balance sheets, statements of operations, or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85D_zFgiVJvKT4t1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-12-31"
      decimals="0"
      id="Fact000444"
      unitRef="USD">2983773</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2026-07-222026-07-22" id="Fact000446">a 1-for-20 Reverse Stock Split of the Company&#x2019;s issued and outstanding
common stock, which became effective on August 20, 2026. At the effective time, every 20 shares of common stock were automatically converted
into one share, with fractional shares rounded up to the nearest whole share. The Reverse Stock Split was effected to regain compliance
with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000448">&lt;p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zp3T5pTMGps9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zBYIuU3WOfC"&gt;Basis
of Accounting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying financial statements of the Company have been prepared on the accrual basis of accounting in accordance with Generally Accepted
Accounting Principles in the United States of America (GAAP).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2026-01-01to2026-09-30" id="Fact000450">&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zLf7a1TZQL07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zNa2n2CZnM95"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the Company&#x2019;s unaudited interim financial statements in conformity with accounting principles generally accepted
in the United States of America (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses
during the reporting periods. Significant estimates and assumptions reflected in these interim financial statements are consistent with
those described in the Company&#x2019;s most recent annual financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
estimates and assumptions are based on historical experience and other factors that management believes are reasonable under the circumstances.
Due to the inherent uncertainty involved in making estimates, actual results could differ from those estimates, and such differences
may be material to the financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
evaluates its estimates on an ongoing basis. Changes in estimates are recognized in the period in which they become known and, if applicable,
in future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <CURX:GoingConcernPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000452">&lt;p id="xdx_84C_ecustom--GoingConcernPolicyTextBlock_zkPlabuTHMY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zOwEfqEFDvGg"&gt;Going
Concern&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the end of each reporting period, management exercises judgment in assessing the Company&#x2019;s ability to continue as a going concern
in accordance with ASC 205-40, Presentation of Financial Statements&#x2014;Going Concern, by reviewing the Company&#x2019;s performance,
resources, and future obligations. This assessment considers conditions and events that are known and reasonably knowable as of the date
the financial statements are issued and involves critical judgments regarding the Company&#x2019;s short and long-term operating budgets,
expected profitability, investment and financing activities, and strategic planning.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did not generate operating revenue during the recent several years and has incurred recurring net losses and negative cash flows
from operations. For the nine months ended September 30, 2026, the Company incurred a net loss of $&lt;span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_di_c20260101__20260930_zmvaLj5pX2Xc" title="Net loss"&gt;9,256,795&lt;/span&gt; and used cash in operating
activities of approximately $&lt;span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn4n6_di_c20260101__20260930_zHyBc9hZjIGe" title="Cas in operating activities"&gt;3.39&lt;/span&gt; million. As of September 30, 2026, the Company had cash and cash equivalents of $&lt;span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20260930_zbGUCJwBDei7" title="Cash and cash equivalents"&gt;1,579,689&lt;/span&gt; and an accumulated
deficit of $&lt;span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20260930_z5qErkuiWc09" title="Accumulated deficit"&gt;14,104,350&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operating expenses for the nine months ended September 30, 2026 were partially funded through the utilization of prepaid
research and development balances, which declined from $&lt;span id="xdx_901_eus-gaap--OtherPrepaidExpenseCurrent_iI_c20251231_zIzSnMnPuWRi" title="Prepaid research and development"&gt;6,166,294&lt;/span&gt; as of December 31, 2025 to $&lt;span id="xdx_903_eus-gaap--OtherPrepaidExpenseCurrent_iI_c20260930_zlVOvhLPzke9" title="Prepaid research and development"&gt;314,783&lt;/span&gt; as of September 30, 2026. As these
prepaid balances are consumed, the Company expects its cash used in operating activities to increase materially. The Company further
expects research and development expenditures to increase in connection with its planned Investigational New Drug application submission
and subsequent clinical trial activities. The September 30, 2026 prepaid R&amp;amp;D balance includes $&lt;span id="xdx_90E_ecustom--PrepaidExpenseResearchAndDevelopmentCurrent_iI_c20260930_zuvBLvifRiak" title="Prepaid R&amp;amp;D balance"&gt;265,682&lt;/span&gt; of noncash consulting service
prepayments for Australian clinical trial feasibility activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on its current operating plan, the Company does not expect its existing cash and cash equivalents to be sufficient to fund operations
for at least twelve months from the date these unaudited interim financial statements are issued. These conditions raise substantial
doubt about the Company&#x2019;s ability to continue as a going concern. Management&#x2019;s plans to address these conditions include
raising additional capital through the issuance of equity or debt securities, pursuing strategic collaborations or out-licensing arrangements
for its product candidates, and reducing or deferring discretionary operating and development expenditures. There can be no assurance
that the Company will be able to obtain additional financing on acceptable terms, or at all. The Company regained compliance with the
Nasdaq minimum bid price requirement on September 3, 2026; its ability to obtain additional financing remains uncertain. Because these
plans are not considered probable of being effectively implemented within the meaning of ASC 205-40, they do not alleviate the substantial
doubt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited interim financial statements have been prepared assuming the Company will continue as a going concern and do not
include any adjustments to the carrying amounts or classification of assets and liabilities that might result from the outcome of this
uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CURX:GoingConcernPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000454"
      unitRef="USD">-9256795</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2026-01-01to2026-09-30"
      decimals="-4"
      id="Fact000456"
      unitRef="USD">-3390000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000458"
      unitRef="USD">1579689</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000460"
      unitRef="USD">-14104350</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000462"
      unitRef="USD">6166294</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000464"
      unitRef="USD">314783</us-gaap:OtherPrepaidExpenseCurrent>
    <CURX:PrepaidExpenseResearchAndDevelopmentCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000466"
      unitRef="USD">265682</CURX:PrepaidExpenseResearchAndDevelopmentCurrent>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000468">&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9jcJQbcdAH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zFpdRgWmVJdj"&gt;Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains balances with multiple financial institutions, with balances periodically exceeding the Federal Deposit Insurance Corporation
(FDIC) insurance limit of $&lt;span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20260930_z2o8kYehkB71" title="FDIC insured amount"&gt;250,000&lt;/span&gt; per depositor, per insured bank, for each account ownership category. The management monitors the
cash balances in the operating accounts and adjusts the cash balances as appropriate; however, these cash balances could be impacted
if the underlying financial institutions fail or are subject to other adverse conditions in the financial markets. To date, the Company
has experienced no loss or lack of access to cash in the operating accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000470"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000472">&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z9uCqixWIfE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zFfvO6uUOaT1"&gt;Basic
and Diluted Net Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company computes loss per share in accordance with ASC 260, Earnings per Share, which requires presentation of both basic and diluted
earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common
shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all
dilutive potential common shares outstanding during the period. During the nine months ended September 30, 2026, and 2025, the Company
had no potential dilutive instruments and accordingly basic loss and diluted loss per share are the same.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <CURX:InitialPublicOfferinPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000474">&lt;p id="xdx_840_ecustom--InitialPublicOfferinPolicyTextBlock_zRvWH4gr33S8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zstLZw0sdc8f"&gt;Initial
Public Offering&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company completed its IPO of &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zMAYv1sPgS8" title="Number of shares issued, shares"&gt;187,500&lt;/span&gt; shares of its common stock, par value $&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zbeMdkdIuxv3" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share, at a public offering price of $&lt;span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20260930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z4KsVQctkpOj" title="Sale of stock price per share"&gt;80.00&lt;/span&gt; per
share. This offering generated gross proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20260101__20260930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zZofOuf3CVZ1" title="Gross proceeds"&gt;15.0&lt;/span&gt; million before underwriting discounts, commissions, and other offering expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the IPO, total offering costs were approximately $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn4n6_c20260101__20260930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z45ZqwhPlGB" title="Net proceeds"&gt;2.12&lt;/span&gt; million, consisting of $&lt;span id="xdx_90E_ecustom--UnderwritingDiscountsAndCommissions_pn4n6_c20260101__20260930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zfaZznOQXrL1" title="Underwriting discounts and commissions"&gt;1.41&lt;/span&gt; million in underwriting discounts
and commissions and $&lt;span id="xdx_90B_ecustom--OtherOfferingRelatedExpenses_iI_pn4n6_c20260930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zbPMU4lYhmAe" title="Other offering related expenses"&gt;0.71&lt;/span&gt; million of other offering-related expenses (including legal, accounting, and filing fees). The Company had
previously recorded these other offering costs as deferred IPO costs prior to the effectiveness of the registration statement. Upon the
closing of the IPO, all deferred costs were reclassified and recorded as a reduction to additional paid-in capital (&#x201c;APIC&#x201d;)
within stockholders&#x2019; equity. After deducting total underwriting discounts, commissions, and offering expenses, the Company received
net cash proceeds of approximately $&lt;span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn4n6_c20260101__20260930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zhcrlVZYR8l5" title="Net proceeds"&gt;13.24&lt;/span&gt; million from its IPO. Certain offering costs had been paid by the Company prior to the completion
of the IPO and were recorded as deferred offering costs on the balance sheets prior to being reclassified against additional
paid-in capital upon the consummation of the IPO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CURX:InitialPublicOfferinPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-01-012026-09-30_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000476"
      unitRef="Shares">187500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-30_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000478"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-09-30_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000480"
      unitRef="USDPShares">80.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2026-01-012026-09-30_us-gaap_IPOMember"
      decimals="-5"
      id="Fact000482"
      unitRef="USD">15000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2026-01-012026-09-30_us-gaap_IPOMember"
      decimals="-4"
      id="Fact000484"
      unitRef="USD">2120000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <CURX:UnderwritingDiscountsAndCommissions
      contextRef="From2026-01-012026-09-30_us-gaap_IPOMember"
      decimals="-4"
      id="Fact000486"
      unitRef="USD">1410000</CURX:UnderwritingDiscountsAndCommissions>
    <CURX:OtherOfferingRelatedExpenses
      contextRef="AsOf2026-09-30_us-gaap_IPOMember"
      decimals="-4"
      id="Fact000488"
      unitRef="USD">710000</CURX:OtherOfferingRelatedExpenses>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2026-01-012026-09-30_us-gaap_IPOMember"
      decimals="-4"
      id="Fact000490"
      unitRef="USD">13240000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <CURX:OverAllotmentOptionPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000492">&lt;p id="xdx_847_ecustom--OverAllotmentOptionPolicyTextBlock_zJdxzidglPze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zRjZmg9juQKe"&gt;Over-Allotment
Option&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 12, 2025, the underwriters exercised their option to purchase an additional &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250912__20250912__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zlFEjEsJgSkh" title="Number of shares issued, shares"&gt;28,125&lt;/span&gt; shares of the Company&#x2019;s common
stock at the same public offering price of $&lt;span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250912__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_ztW6h6NJgWN1" title="Sale of stock price per share"&gt;80.00&lt;/span&gt; per share, resulting in gross proceeds of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn4n6_c20250912__20250912__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zMEbJv27eOZ6" title="Gross proceeds"&gt;2.25&lt;/span&gt; million. The Company incurred
$&lt;span id="xdx_904_ecustom--UnderwritingDiscountsAndCommissions_pn4n6_c20250912__20250912__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zQ7k4hBkMkm8" title="Underwriting discounts and commissions"&gt;0.18&lt;/span&gt; million in underwriting discounts and commissions related to the option exercise. After deducting these offering costs, the
Company received net proceeds of $&lt;span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn4n6_c20250912__20250912__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zCwATVtXKDff" title="Net proceeds"&gt;2.07&lt;/span&gt; million. All costs directly attributable to the over-allotment exercise were likewise
recorded as a reduction of APIC within stockholders&#x2019; equity, consistent with the accounting for the initial
closing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CURX:OverAllotmentOptionPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-09-122025-09-12_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact000494"
      unitRef="Shares">28125</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-09-12_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact000496"
      unitRef="USDPShares">80.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-09-122025-09-12_us-gaap_OverAllotmentOptionMember"
      decimals="-4"
      id="Fact000498"
      unitRef="USD">2250000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <CURX:UnderwritingDiscountsAndCommissions
      contextRef="From2025-09-122025-09-12_us-gaap_OverAllotmentOptionMember"
      decimals="-4"
      id="Fact000500"
      unitRef="USD">180000</CURX:UnderwritingDiscountsAndCommissions>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-09-122025-09-12_us-gaap_OverAllotmentOptionMember"
      decimals="-4"
      id="Fact000502"
      unitRef="USD">2070000.00</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2026-01-01to2026-09-30" id="Fact000504">&lt;p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zlXgNSXLhvz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zmPAyu7kCsVg"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
820 Fair Value Measurements and Disclosures establishes a framework for all fair value measurements and expands disclosures related to
fair value measurement and developments. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer
a liability in an orderly transaction between market participants at the measurement date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
820 requires that assets and liabilities measured at fair value are classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 &#x2013;
    Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 &#x2013; Inputs
    other than quoted prices that are observable for the asset or liability either directly or indirectly; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 &#x2013; Inputs
    that are not based on observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of cash and accrued liabilities approximate fair value because of the short-term nature of these items.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000506">&lt;p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_zOvJizUtYjv" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zymEQDna1Ho3"&gt;Leases
&amp;amp; Right of Use Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted ASC 842 Leases on January 1, 2022. At inception of a contract, the Company assesses whether a contract is, or contains,
a lease. Contracts that convey the right to control the use of an identified asset for a period of time in exchange for consideration
are accounted for as leases giving rise to right-of-use assets. At the commencement date, a right-of-use asset is measured at cost, where
cost comprises: (a) the amount of the initial measurement of the lease liability; (b) any lease payments made at or before the commencement
date, less any lease incentives received; (c) any initial direct costs incurred by the Company; and (d) an estimate of costs to be incurred
by the Company in dismantling and removing the underlying asset, restoring the site on which it is located or restoring the underlying
asset to the condition required by the terms and conditions of the lease, unless those costs are incurred to produce inventories.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
lease liability is initially measured at the present value of the unpaid lease payments. Subsequently, the Company measures a lease liability
by: (a) increasing the carrying amount to reflect interest on the lease liability; (b) reducing the carrying amount to reflect the lease
payments made; and (c) re-measuring the carrying amount to reflect any reassessment or lease modifications, or to reflect revised in-substance
fixed lease payments. Each lease payment is allocated between repayment of the lease principal and interest. Interest on the lease liability
in each period during the lease term is allocated to produce a constant periodic rate of interest on the remaining balance of the lease
liability. Except where the costs are included in the carrying amount of another asset, the Company recognizes in profit or loss (a)
the interest on a lease liability and (b) variable lease payments not included in the measurement of a lease liability in the period
in which the event or condition that triggers those payments occurs. The Company subsequently measures a right-of-use asset at cost less
any accumulated amortization and any accumulated impairment losses; and adjusted for any re-measurement of the lease liability. Right-of-use
assets are depreciated over the shorter of the asset&#x2019;s useful life and the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2026-01-01to2026-09-30" id="Fact000508">&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_z0jjtmjCokB4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zelh8N631bAa"&gt;Research
and Development Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for research and development (&#x201c;R&amp;amp;D&#x201d;) costs in accordance with ASC 730, Research and Development. R&amp;amp;D
costs are expensed as incurred unless they represent nonrefundable advance payments for goods or services to be received in the future.
Nonrefundable advance payments to third parties&#x2014;such as Contract Research Organizations (&#x201c;CROs&#x201d;), Contract Development
and Manufacturing Organizations (&#x201c;CDMOs&#x201d;), clinical sites, and other service providers&#x2014;are recorded as prepaid expenses
and recognized in R&amp;amp;D expense as the related services are performed, generally over the contractual period of performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;R&amp;amp;D
expense primarily includes employee-related costs (salaries, benefits, and stock-based compensation) for personnel engaged in R&amp;amp;D;
fees to CROs, CDMOs, consultants, and other third parties; clinical trial and preclinical study costs; and costs to manufacture and test
preclinical and clinical materials. The Company records accruals for services performed but not yet invoiced based on estimates of work
completed, patient enrollment/visits, manufacturing progress, and data from vendors. Up-front set-up or activation fees under executory
service arrangements are deferred and recognized over the expected period of performance. Materials, equipment, and licenses with no
alternative future use are expensed when incurred; items with alternative future use are capitalized and recognized in accordance with
the applicable guidance. Prepaid R&amp;amp;D balances are evaluated for recoverability and adjusted for changes in project scope, timing,
or cancellations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2026-01-01to2026-09-30" id="Fact000510">&lt;p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zUzdvfV8KmFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z4N2u5YG5C5j"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based compensation in accordance with ASC 718, Compensation&#x2014;Stock Compensation. Share-based payment
awards granted to employees, non-employee directors and non-employee service providers are measured at the grant-date fair value of the
award and recognized as compensation expense over the requisite service period, which is generally the vesting period. Employee awards
that are fully vested on the grant date are expensed in full at that date. For nonemployee awards, the corresponding cost is recognized
as an immediate expense or a prepaid asset based on the goods or services acquired and the enforceable rights conveyed by the arrangement.
The fair value of awards of common stock and restricted stock is determined by reference to the closing price of the Company&#x2019;s
common stock as reported on Nasdaq on the grant date. The fair value of stock options, if granted, is estimated using the Black-Scholes
option-pricing model, which requires management to make assumptions regarding the expected term, expected volatility, risk-free interest
rate and expected dividend yield. Because the Company has limited trading history, expected volatility is estimated by reference to the
historical volatility of a group of comparable publicly traded companies. The Company has elected to account for forfeitures as they
occur. Stock-based compensation expense is classified within research and development expense or general and administrative expense based
on the function of the recipient&#x2019;s services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
fully vested nonemployee consulting shares issued during the third quarter of 2026 in exchange for enforceable rights to future services,
the Company recognizes prepaid services at grant-date fair value and recognizes the related expense as services are received over the
contractual service periods. Immediate vesting of the shares does not accelerate recognition of services not yet received.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000512">&lt;p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zES7fJeR0lB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z6wkQ4f10mhl"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes under ASC 740, Income Taxes. This standard requires the Company to use the asset and liability method,
which involves making estimates and assumptions and exercising judgment regarding the carrying values of assets and liabilities. These
values are subject to inherent accounting estimates, the interpretation of income tax legislation across various jurisdictions, expectations
about future operating results, the timing of reversal of temporary differences, and potential audits of income tax filings by tax authorities.
Deferred tax assets and liabilities are recognized for the future tax consequences of differences between the financial statement carrying
amounts of existing assets and liabilities and their respective tax bases. These assets and liabilities are measured using enacted tax
rates expected to apply to taxable income in the years when those temporary differences are expected to be recovered or settled. The
impact of changes in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment
date. Valuation allowances are established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
the Company incurs losses for income tax purposes, it assesses the probability of future taxable income based on budgeted forecasts.
These forecasts are adjusted to account for non-taxable income and expenses and specific rules on the use of unused credits and tax losses.
If the forecasts indicate that sufficient future taxable income will not be available to deduct the temporary differences, a deferred
tax asset is not recognized for all deductible temporary differences.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <CURX:RelatedPartyTransactionsPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000514">&lt;p id="xdx_843_ecustom--RelatedPartyTransactionsPolicyTextBlock_zNPjgo4uLI1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zS9BiIQqMkNi"&gt;Related
Party Transactions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company identifies and accounts for related party transactions, disclosing them in accordance with ASC 850, Related Party Disclosures,
and other relevant ASC standards. Parties are considered related to the Company if they, directly or indirectly, through one or more
intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include the principal
owners of the Company, its management, members of the immediate families of the principal owners and management, and other parties with
which the Company may engage in transactions if one party controls or can significantly influence the management or operating policies
of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CURX:RelatedPartyTransactionsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000516">&lt;p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zavHd2VeqH42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zEP87z6R8M4j"&gt;Segment
Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision
maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources and in assessing performance. The Company&#x2019;s Chief Executive Officer
is its CODM. The Company&#x2019;s CODM uses GAAP financial statements for the purposes of making operating decisions, allocating resources
and evaluating financial performance. As such, the Company has determined that it operates in &lt;span id="xdx_90C_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20260101__20260930_zpIsQorWPKc3" title="Number of operating segment"&gt;one&lt;/span&gt; operating and &lt;span id="xdx_90A_eus-gaap--NumberOfReportableSegments_pid_dc_uSegment_c20260101__20260930_zgeBUlBL0Rvl" title="Number of reportable segment"&gt;one&lt;/span&gt; reportable segment.
The Company&#x2019;s long-lived assets are entirely based in the United States.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000518"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000520"
      unitRef="Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000522">&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zy26HT8vnM93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zJoUWDXIdmG4"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is classified as an &#x201c;emerging growth company&#x201d; (EGC) under the Jumpstart Our Business Startups Act of 2012 (the JOBS
Act). This classification allows EGCs to delay adopting new or revised accounting standards issued after the enactment of the JOBS Act
until these standards apply to private companies. The Company has chosen to delay the adoption of these new or revised accounting standards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is classified as a &#x201c;smaller reporting company&#x201d; (SRC) under the Securities and Exchange Commission (SEC) regulations.
This classification allows SRCs to provide scaled disclosures in their SEC filings, including reduced financial statement and executive
compensation disclosure requirements. The Company has elected to take advantage of these scaled disclosure requirements to simplify its
reporting processes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluated the impact of ASU 2024-03, &lt;i&gt;Disaggregation of Income Statement Expenses&lt;/i&gt;, issued by the Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) in November 2024. The update requires additional disclosures to provide disaggregated
information about certain expense captions presented in the income statement, including, among other items, inventory, employee compensation,
depreciation, and amortization, to enhance transparency into the nature of expenses. The amendments in ASU 2024-03 are effective for
annual reporting periods beginning after December 15, 2026, and interim periods thereafter, with early adoption permitted. The Company
is currently evaluating the impact that the adoption of this standard will have on its financial statement disclosures. While the standard
is not expected to have an impact on the Company&#x2019;s results of operations, financial position, or cash flows, it is expected to
result in expanded disclosures upon adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No.
2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#x2019;s
effective tax rate reconciliation as well as additional information on income taxes paid. The Company adopted this ASU on a prospective
basis effective January 1, 2025. Refer to Note 5, Income Taxes for the inclusion of new disclosures required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. The amendments consolidate interim
disclosure requirements and clarify the information to be provided about material developments since the last annual reporting period.
They are effective for interim periods within annual periods beginning after December 15, 2027 for public business entities and after
December 15, 2028 for other entities, with early adoption permitted. The Company is evaluating the disclosure effects and the application
of its emerging growth company extended-transition election.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Apart
from as mentioned above, management does not believe that other recently issued but not yet effective accounting standards, if currently
adopted, would have a material effect on the Company&#x2019;s balance sheets, statements of operations, or cash flows.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000524">&lt;p id="xdx_809_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zrRYPmVtNJI1" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_826_zf5TEQqME25i"&gt;Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zQyH7kRpJes9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of accrued expenses is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zjBtsE0N5qa8"&gt;Schedule
of Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - Condensed Consolidated Balance Sheets"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20260930_zSjzh1ya19S6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20251231_zGODMcWWsZh9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_maALCANzeP1_zh0tQz4Sr5Yd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accounting fees&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0528"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;550&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedPayrollTaxesCurrentAndNoncurrent_iI_maALCANzeP1_zg3EUnxonwR4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Payroll expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedRentCurrent_iI_maALCANzeP1_zuNpWdaBTrnh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Rent&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0534"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--TaxesPayableCurrentAndNoncurrent_iI_maALCANzeP1_zT4YUCWEcpik" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Tax fees&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0537"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iTI_mtALCANzeP1_zVjQmsSQTwQi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total Accrued Expenses&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;9,741&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;11,915&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zeHyFZs65Mw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000526">&lt;p id="xdx_893_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zQyH7kRpJes9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of accrued expenses is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zjBtsE0N5qa8"&gt;Schedule
of Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - Condensed Consolidated Balance Sheets"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20260930_zSjzh1ya19S6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20251231_zGODMcWWsZh9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_maALCANzeP1_zh0tQz4Sr5Yd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accounting fees&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0528"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;550&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedPayrollTaxesCurrentAndNoncurrent_iI_maALCANzeP1_zg3EUnxonwR4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Payroll expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedRentCurrent_iI_maALCANzeP1_zuNpWdaBTrnh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Rent&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0534"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--TaxesPayableCurrentAndNoncurrent_iI_maALCANzeP1_zT4YUCWEcpik" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Tax fees&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0537"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iTI_mtALCANzeP1_zVjQmsSQTwQi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total Accrued Expenses&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;9,741&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;11,915&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000529"
      unitRef="USD">550</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000531"
      unitRef="USD">9741</us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent>
    <us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000532"
      unitRef="USD">9741</us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent>
    <us-gaap:AccruedRentCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000535"
      unitRef="USD">1599</us-gaap:AccruedRentCurrent>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000538"
      unitRef="USD">25</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000540"
      unitRef="USD">9741</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000541"
      unitRef="USD">11915</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <CURX:PrepaidExpensesTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000543">&lt;p id="xdx_808_ecustom--PrepaidExpensesTextBlock_zPMvAQFHgvPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
&lt;span id="xdx_823_ztWdedqV8igb"&gt;Prepaid expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_ecustom--PrepaidExpenseTableTextBlock_zehPndnofri3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of prepaid expenses is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zzOTe8JoQ7tf"&gt;Schedule
of Prepaid Expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - Condensed Consolidated Balance Sheets"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20260930_z938eizd5A0e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20251231_zXx0Cya1vPCa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PrepaidInsurance_iI_maPECzZop_zkktdnXLWZ5i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;125,538&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;80,232&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--PrepaidResearchAndDevelopment_iI_maPECzZop_z6gc8T12gMze" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;R&amp;amp;D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;314,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,166,294&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--OtherPrepaidExpensesCurrent_iI_maPECzZop_zPwYf2Skj2f3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;536,380&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,848&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidExpenseCurrent_iTI_mtPECzZop_zE6AQDizFPf1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total Prepaid Expenses&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;976,701&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;6,254,374&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zW6K9Tk39rm2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CURX:PrepaidExpensesTextBlock>
    <CURX:PrepaidExpenseTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000545">&lt;p id="xdx_894_ecustom--PrepaidExpenseTableTextBlock_zehPndnofri3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of prepaid expenses is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zzOTe8JoQ7tf"&gt;Schedule
of Prepaid Expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - Condensed Consolidated Balance Sheets"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20260930_z938eizd5A0e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20251231_zXx0Cya1vPCa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PrepaidInsurance_iI_maPECzZop_zkktdnXLWZ5i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;125,538&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;80,232&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--PrepaidResearchAndDevelopment_iI_maPECzZop_z6gc8T12gMze" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;R&amp;amp;D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;314,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,166,294&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--OtherPrepaidExpensesCurrent_iI_maPECzZop_zPwYf2Skj2f3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;536,380&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,848&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidExpenseCurrent_iTI_mtPECzZop_zE6AQDizFPf1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total Prepaid Expenses&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;976,701&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;6,254,374&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CURX:PrepaidExpenseTableTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000547"
      unitRef="USD">125538</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000548"
      unitRef="USD">80232</us-gaap:PrepaidInsurance>
    <CURX:PrepaidResearchAndDevelopment
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000550"
      unitRef="USD">314783</CURX:PrepaidResearchAndDevelopment>
    <CURX:PrepaidResearchAndDevelopment
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000551"
      unitRef="USD">6166294</CURX:PrepaidResearchAndDevelopment>
    <CURX:OtherPrepaidExpensesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000553"
      unitRef="USD">536380</CURX:OtherPrepaidExpensesCurrent>
    <CURX:OtherPrepaidExpensesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000554"
      unitRef="USD">7848</CURX:OtherPrepaidExpensesCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000556"
      unitRef="USD">976701</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000557"
      unitRef="USD">6254374</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000559">&lt;p id="xdx_80E_eus-gaap--LesseeOperatingLeasesTextBlock_zsBubILnOCZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.
&lt;span id="xdx_823_zY5M0GRHgdk3"&gt;Lease&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 1, 2025, the Company assumed an office lease from Duraviva Pharma Inc. (&#x201c;Duraviva&#x201d;), a New York corporation under
common control, through a lease assignment agreement. &lt;span id="xdx_906_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20250101__20250101_zCTmjSKXoPej" title="Operating lease term extend"&gt;The lease term extends through August 31, 2026.&lt;/span&gt; On August 13, 2026, the Company
executed a lease amendment extending the term through September 30, 2031. The Company classified the lease as an operating lease. Upon
adoption of ASC 842, the Company recognized right-of-use asset and corresponding lease liability for its operating lease. The lease extension
was accounted for under ASC 842 effective September 1, 2026, resulting in an additional right-of-use asset and lease liability of $&lt;span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20260901_zczBu9s7HkEl" title="Right of use asset and lease liability"&gt;295,558&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the fourth quarter of 2025, the Company entered into lease agreements for three motor vehicles with non-cancelable lease terms ranging
from &lt;span id="xdx_909_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember__srt--RangeAxis__srt--MinimumMember_zUURdVIX6ZXk" title="Lease term"&gt;36&lt;/span&gt; to &lt;span id="xdx_909_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember__srt--RangeAxis__srt--MaximumMember_zXWIxppOfEH1" title="Lease term"&gt;51&lt;/span&gt; months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zOiD8bIFIHef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following summarizes information about the Company&#x2019;s lease as of September 30, 2026 and December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zQ3gbGAixI2c"&gt;Schedule
of Lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20260701__20260930_zCuOfpnXjPeh" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250701__20250930_z6CPAI23wSVl" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Three Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Amount recognized in the income statements&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseExpense_zz6jA8aZMJ4k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Operating lease expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;40,278&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,404&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20260101__20260930_zSbYsRjwegVd" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250101__20250930_zU4xP0hpRxU1" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Nine Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Amount recognized in the income statements&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseExpense_zEyZTGfBUIGg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Operating lease expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;120,216&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;52,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20260930_zUVFgx0TxCW6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20251231_zJrkpvWpDCvg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Amount recognized in the balance sheets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zZyqu9UsFAh1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;540,622&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;352,616&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseLiability_iI_z43i4CV5BPpe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;542,090&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;346,699&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Amount recognized in the income statements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--CashPaidForOperatingLeaseLiability_iI_zvyVi5Qch45g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;114,430&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;93,957&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Lease commitment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz6oL_z7ApntaxoXva" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;38,343&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;136,921&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz6oL_zG49AtXNA3i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154,008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,964&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz6oL_zFafdzrxim2j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86,766&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz6oL_zNRtWtRvpMnh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;129,022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,078&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz6oL_zAaAsra7KyFj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,982&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0599"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz6oL_zlaoIqiDanyb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Thereafter (2031)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;53,704&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0602"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz6oL_zQ57bE6HNTRd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;599,389&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;374,729&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zoDsRbEAaPm5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(57,299&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(28,030&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseLiability_iI_zJzxYa07Kif6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;542,090&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;346,699&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Supplement information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20260930_z1PjupJ1m7mf" title="Weighted average discount rate"&gt;4.87&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_z1UeJcH76PHi" title="Weighted average discount rate"&gt;5.47&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Remaining lease term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20260930_ziDQplcgNBw4" title="Weight average remaining lease term"&gt;49&lt;/span&gt; months &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20251231_zLPzgOrLC3ba" title="Weight average remaining lease term"&gt;47&lt;/span&gt; months&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zLpQkTFo2K0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="From2025-01-012025-01-01" id="Fact000561">The lease term extends through August 31, 2026.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2026-09-01"
      decimals="0"
      id="Fact000563"
      unitRef="USD">295558</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2025-12-31_us-gaap_VehiclesMember_srt_MinimumMember"
      id="Fact000565">P36M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2025-12-31_us-gaap_VehiclesMember_srt_MaximumMember"
      id="Fact000567">P51M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000569">&lt;p id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zOiD8bIFIHef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following summarizes information about the Company&#x2019;s lease as of September 30, 2026 and December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zQ3gbGAixI2c"&gt;Schedule
of Lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20260701__20260930_zCuOfpnXjPeh" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250701__20250930_z6CPAI23wSVl" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Three Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Amount recognized in the income statements&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseExpense_zz6jA8aZMJ4k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Operating lease expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;40,278&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,404&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20260101__20260930_zSbYsRjwegVd" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250101__20250930_zU4xP0hpRxU1" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Nine Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Amount recognized in the income statements&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseExpense_zEyZTGfBUIGg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Operating lease expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;120,216&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;52,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20260930_zUVFgx0TxCW6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20251231_zJrkpvWpDCvg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Amount recognized in the balance sheets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zZyqu9UsFAh1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;540,622&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;352,616&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseLiability_iI_z43i4CV5BPpe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;542,090&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;346,699&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Amount recognized in the income statements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--CashPaidForOperatingLeaseLiability_iI_zvyVi5Qch45g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;114,430&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;93,957&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Lease commitment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz6oL_z7ApntaxoXva" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;38,343&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;136,921&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz6oL_zG49AtXNA3i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154,008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,964&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz6oL_zFafdzrxim2j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86,766&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz6oL_zNRtWtRvpMnh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;129,022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,078&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz6oL_zAaAsra7KyFj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,982&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0599"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz6oL_zlaoIqiDanyb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Thereafter (2031)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;53,704&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0602"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz6oL_zQ57bE6HNTRd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;599,389&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;374,729&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zoDsRbEAaPm5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(57,299&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(28,030&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseLiability_iI_zJzxYa07Kif6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;542,090&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;346,699&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Supplement information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20260930_z1PjupJ1m7mf" title="Weighted average discount rate"&gt;4.87&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_z1UeJcH76PHi" title="Weighted average discount rate"&gt;5.47&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Remaining lease term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20260930_ziDQplcgNBw4" title="Weight average remaining lease term"&gt;49&lt;/span&gt; months &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20251231_zLPzgOrLC3ba" title="Weight average remaining lease term"&gt;47&lt;/span&gt; months&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000571"
      unitRef="USD">40278</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000572"
      unitRef="USD">17404</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000574"
      unitRef="USD">120216</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000575"
      unitRef="USD">52211</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000577"
      unitRef="USD">540622</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000578"
      unitRef="USD">352616</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000580"
      unitRef="USD">542090</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000581"
      unitRef="USD">346699</us-gaap:OperatingLeaseLiability>
    <CURX:CashPaidForOperatingLeaseLiability
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000583"
      unitRef="USD">114430</CURX:CashPaidForOperatingLeaseLiability>
    <CURX:CashPaidForOperatingLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000584"
      unitRef="USD">93957</CURX:CashPaidForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000586"
      unitRef="USD">38343</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000587"
      unitRef="USD">136921</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000589"
      unitRef="USD">154008</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000590"
      unitRef="USD">89964</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000592"
      unitRef="USD">154330</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000593"
      unitRef="USD">86766</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000595"
      unitRef="USD">129022</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000596"
      unitRef="USD">61078</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000598"
      unitRef="USD">69982</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000601"
      unitRef="USD">53704</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000604"
      unitRef="USD">599389</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000605"
      unitRef="USD">374729</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000607"
      unitRef="USD">57299</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000608"
      unitRef="USD">28030</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000610"
      unitRef="USD">542090</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000611"
      unitRef="USD">346699</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000613"
      unitRef="Pure">0.0487</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000615"
      unitRef="Pure">0.0547</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2026-09-30" id="Fact000617">P49M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2025-12-31" id="Fact000619">P47M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000621">&lt;p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_z8dI0kPn0sge" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_828_zBuwZACrQRr5"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the Company&#x2019;s net losses and the valuation allowance provided on the related deferred tax assets, there were no provisions for
income taxes for the nine months ended September 30, 2026 and 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zx439VeBnWml" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of income tax provision (benefit) for the nine months ended September 30, 2026 and 2025 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zjwuub9EKHgk" style="display: none"&gt;Schedule
of Components of Income Tax Provision (benefit)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: justify; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20260701__20260930_zpT1pvJVGL57" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250701__20250930_zaszoKmlyemd" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Three Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_z8LoqazKDAza" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Current income tax expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCITEBzGHy_z8SFTdoYuht3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: justify"&gt;Federal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0628"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCITEBzGHy_zZhXK7QYnAPi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;State and local&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0631"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0632"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzGHy_maITEBzdkK_zUxi1SWIVKj7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Total current income tax expense:&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0634"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0635"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zdNPcf6rPQv" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Deferred income tax expense (benefit)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBzSjH_ze04siE2hn54" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0640"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0641"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBzSjH_zsZ64n94UvUl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;State and local&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0643"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0644"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzSjH_maITEBzdkK_zgdcuzLEXtm1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Total deferred income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0646"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzdkK_zDEibZllr72l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total income tax provision (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0649"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0650"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: justify; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20260101__20260930_zPAbvKmBSiS7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250101__20250930_zL5NzAy1x51" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the nine Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zKut6KhrL7Sl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Current income tax expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCITEBzGHy_z68l37nASnHb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: justify"&gt;Federal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0656"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCITEBzGHy_ze2HocdLS6A8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;State and local&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0658"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0659"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzGHy_maITEBzdkK_zgwswofgWAud" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Total current income tax expense:&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0661"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0662"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zNGOWWnqe7u9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Deferred income tax expense (benefit)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBzSjH_z4hTUFjC6P2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0667"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0668"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBzSjH_zaWoAhH0DoBj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;State and local&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0670"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzSjH_maITEBzdkK_zmAJe4rbNiL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Total deferred income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0673"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0674"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzdkK_zxRG203zZBnh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total income tax provision (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0676"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0677"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zauAK4mXPGXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z2Wyl8qjBSM2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents a reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective tax rate for
the nine months ended September 30, 2026 and 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zsUky0ooTPke" style="display: none"&gt;Schedule
of Reconciliation of Effective Tax Rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Three Months Ended&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Three Months Ended&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;U.S. federal statutory tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20260701__20260930_zzS5SkbrA5X7" style="width: 12%; text-align: right" title="U.S. federal statutory tax rate"&gt;(591,275&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maITEBzPrf_c20260701__20260930_zyBKkyFEHwn9" style="width: 12%; text-align: right" title="U.S. federal statutory tax rate, percent"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20250701__20250930_zsh9SQZ7BiYj" style="width: 12%; text-align: right" title="U.S. federal statutory tax rate"&gt;(200,352&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maITEBzPrf_c20250701__20250930_zT6MN2LjLDn9" style="width: 12%; text-align: right" title="U.S. federal statutory tax rate, percent"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State and local income taxes, net of federal effect&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20260701__20260930_zYDcJz3v4uv3" style="text-align: right" title="State and local income taxes, net of federal effect"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0689"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maITEBzPrf_c20260701__20260930_zfqFLH4ehali" style="text-align: right" title="State and local income taxes, net of federal effect, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0691"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20250701__20250930_z9Qcp4TvrfBk" style="text-align: right" title="State and local income taxes, net of federal effect"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0693"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maITEBzPrf_c20250701__20250930_zMbaMFOXZnZ" style="text-align: right" title="State and local income taxes, net of federal effect, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0695"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Nontaxable or nondeductible items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_c20260701__20260930_zErYsyNLPSce" style="text-align: right" title="Nontaxable or nondeductible items"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0697"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_maITEBzPrf_c20260701__20260930_zuaduKL7z9ka" style="text-align: right" title="Nontaxable or nondeductible items, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0699"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_c20250701__20250930_zRznnjx2SMj5" style="text-align: right" title="Nontaxable or nondeductible items"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0701"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_maITEBzPrf_c20250701__20250930_zGEXDXJt8DEi" style="text-align: right" title="Nontaxable or nondeductible items, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0703"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Changes in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_di_c20260701__20260930_zkBJosGq8jc6" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance"&gt;591,275&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_maITEBzPrf_c20260701__20260930_zH71rrYk9eoa" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance, percent"&gt;-21.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_di_c20250701__20250930_z4Tk6iHjWO88" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance"&gt;200,352&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_maITEBzPrf_c20250701__20250930_zmTFJzCWP1Rj" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance, percent"&gt;-21.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Income tax expense and effective tax rate&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncomeTaxExpenseBenefit_iT_c20260701__20260930_zOZsb9bIF3w9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expense and effective tax rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0713"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mtITEBzPrf_c20260701__20260930_ztIhivaP3bpd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expense and effective tax rate, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0715"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IncomeTaxExpenseBenefit_iT_c20250701__20250930_zpv51xnI1WIa" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expense and effective tax rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0717"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mtITEBzPrf_c20250701__20250930_zHhR789Nn5pg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expense and effective tax rate, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0719"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Nine Months Ended&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Nine Months Ended&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;U.S. federal statutory tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20260101__20260930_zIaxTiyt9tIc" style="width: 12%; text-align: right" title="U.S. federal statutory tax rate"&gt;(1,943,927&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maITEBzPrf_c20260101__20260930_zQfQbfafeBY7" style="width: 12%; text-align: right" title="U.S. federal statutory tax rate, percent"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20250101__20250930_zrjS3kfVvR6c" style="width: 12%; text-align: right" title="U.S. federal statutory tax rate"&gt;(241,918&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maITEBzPrf_c20250101__20250930_zcz8nYjVUkdh" style="width: 12%; text-align: right" title="U.S. federal statutory tax rate, percent"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State and local income taxes, net of federal effect&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20260101__20260930_zviEWVBzdn24" style="text-align: right" title="State and local income taxes, net of federal effect"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0729"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maITEBzPrf_c20260101__20260930_zMzPsBbGT2Tl" style="text-align: right" title="State and local income taxes, net of federal effect, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0731"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20250101__20250930_zfzLO3cCQej" style="text-align: right" title="State and local income taxes, net of federal effect"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0733"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maITEBzPrf_c20250101__20250930_zQk0cCb6bNO4" style="text-align: right" title="State and local income taxes, net of federal effect, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0735"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Nontaxable or nondeductible items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_c20260101__20260930_zzywxt0eHWL7" style="text-align: right" title="Nontaxable or nondeductible items"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0737"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_maITEBzPrf_c20260101__20260930_zvdAeHVkcab8" style="text-align: right" title="Nontaxable or nondeductible items, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_c20250101__20250930_zUQtCJ5uqMW5" style="text-align: right" title="Nontaxable or nondeductible items"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0741"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_maITEBzPrf_c20250101__20250930_zlo4oKmmCRv5" style="text-align: right" title="Nontaxable or nondeductible items, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0743"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Changes in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_di_c20260101__20260930_ziOCxIeyJbbl" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance"&gt;1,943,927&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_maITEBzPrf_c20260101__20260930_zllVXj03HAV5" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance, percent"&gt;-21.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_di_c20250101__20250930_zFDezSTD8SC" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance"&gt;241,918&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_maITEBzPrf_c20250101__20250930_zoLyrYmQaN1e" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance, percent"&gt;-21.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Income tax expense and effective tax rate&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxExpenseBenefit_iT_c20260101__20260930_zwsiuPWuV3Hj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expense and effective tax rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0753"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mtITEBzPrf_c20260101__20260930_zjL5q5cXRUB5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expense and effective tax rate, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0755"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IncomeTaxExpenseBenefit_iT_c20250101__20250930_zxSM6MMrYGwd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expense and effective tax rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0757"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mtITEBzPrf_c20250101__20250930_zA4b8qiYdES5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expense and effective tax rate, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0759"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z0MFrzng7gKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zsmxzYnkJDff" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income tax assets as of September 30, 2026 and December 31, 2025, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zNr6cCu3l72e"&gt;Schedule
of Deferred Income Tax Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20260930_zPMmgv8XCsie" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20251231_zkhL5LUXCGh2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGz12Q_zdiS3lkxX5J5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net operating losses carry forwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,961,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,017,359&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOtherTaxCarryforwards_iI_maDTAGz12Q_zCLPRAVjpgSg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,056&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0767"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGz12Q_maDTANzGAl_zQ3137UKUBT2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,963,342&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,017,359&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzGAl_zavHf2owuUUe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,963,342&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,017,359&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsNet_iNTI_di_mtDTANzGAl_z68GoZnFajvj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0775"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0776"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_z2flc81WMxY7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
assessing the realization of deferred tax assets, management evaluates whether it is more likely than not that some or all of these assets
will not be realized. The ultimate realization of deferred tax assets depends on generating future taxable income during the periods
when these temporary differences become deductible.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the available objective evidence, management believes it is more likely than not that the net deferred tax assets will not be realizable.
Accordingly, the Company has applied a full valuation allowance against its net deferred tax assets as of September 30, 2026 and December
31, 2025. The net change in the total valuation allowance between December 31, 2025, and September 30, 2026, was an increase of $&lt;span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20250101__20251231_zhoSlrF48St6" title="Valuation allowance"&gt;&lt;span id="xdx_909_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20260101__20260930_z0wuPMYW3Nr9" title="Valuation allowance"&gt;1,945,983&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to U.S. federal and state income tax examinations by the Internal Revenue Service (IRS) and relevant state tax authorities.
The Company is incorporated in the state of Nevada, which does not impose a corporate income tax.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.
As of September 30, 2026, and December 31, 2025, the Company did not have any significant uncertain tax positions or unrecognized tax
benefits. Additionally, as of September 30, 2026, and December 31, 2025, the Company has federal net operating loss carryforwards of
$&lt;span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_c20260930_zE7qgcNWFUug" title="Net operating loss carry forwards"&gt;14,101,362&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_c20251231_zABtnTGk1K4g" title="Net operating loss carry forwards"&gt;4,847,550&lt;/span&gt;, respectively, for tax purposes. These net operating loss carryforwards may be carried forward indefinitely;
however, their utilization may be subject to limitations under Section 382 of the Internal Revenue Code in the event of a change in ownership.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000623">&lt;p id="xdx_89E_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zx439VeBnWml" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of income tax provision (benefit) for the nine months ended September 30, 2026 and 2025 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zjwuub9EKHgk" style="display: none"&gt;Schedule
of Components of Income Tax Provision (benefit)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: justify; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20260701__20260930_zpT1pvJVGL57" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250701__20250930_zaszoKmlyemd" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Three Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_z8LoqazKDAza" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Current income tax expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCITEBzGHy_z8SFTdoYuht3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: justify"&gt;Federal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0628"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCITEBzGHy_zZhXK7QYnAPi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;State and local&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0631"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0632"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzGHy_maITEBzdkK_zUxi1SWIVKj7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Total current income tax expense:&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0634"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0635"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zdNPcf6rPQv" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Deferred income tax expense (benefit)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBzSjH_ze04siE2hn54" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0640"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0641"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBzSjH_zsZ64n94UvUl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;State and local&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0643"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0644"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzSjH_maITEBzdkK_zgdcuzLEXtm1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Total deferred income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0646"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzdkK_zDEibZllr72l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total income tax provision (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0649"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0650"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: justify; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20260101__20260930_zPAbvKmBSiS7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250101__20250930_zL5NzAy1x51" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the nine Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zKut6KhrL7Sl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Current income tax expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCITEBzGHy_z68l37nASnHb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: justify"&gt;Federal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0656"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCITEBzGHy_ze2HocdLS6A8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;State and local&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0658"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0659"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzGHy_maITEBzdkK_zgwswofgWAud" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Total current income tax expense:&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0661"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0662"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zNGOWWnqe7u9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Deferred income tax expense (benefit)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBzSjH_z4hTUFjC6P2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0667"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0668"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBzSjH_zaWoAhH0DoBj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;State and local&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0670"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzSjH_maITEBzdkK_zmAJe4rbNiL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Total deferred income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0673"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0674"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzdkK_zxRG203zZBnh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total income tax provision (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0676"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0677"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000679">&lt;p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z2Wyl8qjBSM2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents a reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective tax rate for
the nine months ended September 30, 2026 and 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zsUky0ooTPke" style="display: none"&gt;Schedule
of Reconciliation of Effective Tax Rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Three Months Ended&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Three Months Ended&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;U.S. federal statutory tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20260701__20260930_zzS5SkbrA5X7" style="width: 12%; text-align: right" title="U.S. federal statutory tax rate"&gt;(591,275&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maITEBzPrf_c20260701__20260930_zyBKkyFEHwn9" style="width: 12%; text-align: right" title="U.S. federal statutory tax rate, percent"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20250701__20250930_zsh9SQZ7BiYj" style="width: 12%; text-align: right" title="U.S. federal statutory tax rate"&gt;(200,352&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maITEBzPrf_c20250701__20250930_zT6MN2LjLDn9" style="width: 12%; text-align: right" title="U.S. federal statutory tax rate, percent"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State and local income taxes, net of federal effect&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20260701__20260930_zYDcJz3v4uv3" style="text-align: right" title="State and local income taxes, net of federal effect"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0689"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maITEBzPrf_c20260701__20260930_zfqFLH4ehali" style="text-align: right" title="State and local income taxes, net of federal effect, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0691"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20250701__20250930_z9Qcp4TvrfBk" style="text-align: right" title="State and local income taxes, net of federal effect"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0693"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maITEBzPrf_c20250701__20250930_zMbaMFOXZnZ" style="text-align: right" title="State and local income taxes, net of federal effect, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0695"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Nontaxable or nondeductible items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_c20260701__20260930_zErYsyNLPSce" style="text-align: right" title="Nontaxable or nondeductible items"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0697"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_maITEBzPrf_c20260701__20260930_zuaduKL7z9ka" style="text-align: right" title="Nontaxable or nondeductible items, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0699"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_c20250701__20250930_zRznnjx2SMj5" style="text-align: right" title="Nontaxable or nondeductible items"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0701"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_maITEBzPrf_c20250701__20250930_zGEXDXJt8DEi" style="text-align: right" title="Nontaxable or nondeductible items, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0703"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Changes in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_di_c20260701__20260930_zkBJosGq8jc6" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance"&gt;591,275&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_maITEBzPrf_c20260701__20260930_zH71rrYk9eoa" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance, percent"&gt;-21.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_di_c20250701__20250930_z4Tk6iHjWO88" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance"&gt;200,352&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_maITEBzPrf_c20250701__20250930_zmTFJzCWP1Rj" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance, percent"&gt;-21.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Income tax expense and effective tax rate&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncomeTaxExpenseBenefit_iT_c20260701__20260930_zOZsb9bIF3w9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expense and effective tax rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0713"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mtITEBzPrf_c20260701__20260930_ztIhivaP3bpd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expense and effective tax rate, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0715"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IncomeTaxExpenseBenefit_iT_c20250701__20250930_zpv51xnI1WIa" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expense and effective tax rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0717"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mtITEBzPrf_c20250701__20250930_zHhR789Nn5pg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expense and effective tax rate, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0719"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Nine Months Ended&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Nine Months Ended&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;U.S. federal statutory tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20260101__20260930_zIaxTiyt9tIc" style="width: 12%; text-align: right" title="U.S. federal statutory tax rate"&gt;(1,943,927&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maITEBzPrf_c20260101__20260930_zQfQbfafeBY7" style="width: 12%; text-align: right" title="U.S. federal statutory tax rate, percent"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20250101__20250930_zrjS3kfVvR6c" style="width: 12%; text-align: right" title="U.S. federal statutory tax rate"&gt;(241,918&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maITEBzPrf_c20250101__20250930_zcz8nYjVUkdh" style="width: 12%; text-align: right" title="U.S. federal statutory tax rate, percent"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State and local income taxes, net of federal effect&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20260101__20260930_zviEWVBzdn24" style="text-align: right" title="State and local income taxes, net of federal effect"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0729"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maITEBzPrf_c20260101__20260930_zMzPsBbGT2Tl" style="text-align: right" title="State and local income taxes, net of federal effect, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0731"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20250101__20250930_zfzLO3cCQej" style="text-align: right" title="State and local income taxes, net of federal effect"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0733"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maITEBzPrf_c20250101__20250930_zQk0cCb6bNO4" style="text-align: right" title="State and local income taxes, net of federal effect, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0735"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Nontaxable or nondeductible items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_c20260101__20260930_zzywxt0eHWL7" style="text-align: right" title="Nontaxable or nondeductible items"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0737"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_maITEBzPrf_c20260101__20260930_zvdAeHVkcab8" style="text-align: right" title="Nontaxable or nondeductible items, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_c20250101__20250930_zUQtCJ5uqMW5" style="text-align: right" title="Nontaxable or nondeductible items"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0741"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_maITEBzPrf_c20250101__20250930_zlo4oKmmCRv5" style="text-align: right" title="Nontaxable or nondeductible items, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0743"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Changes in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_di_c20260101__20260930_ziOCxIeyJbbl" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance"&gt;1,943,927&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_maITEBzPrf_c20260101__20260930_zllVXj03HAV5" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance, percent"&gt;-21.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_di_c20250101__20250930_zFDezSTD8SC" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance"&gt;241,918&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_maITEBzPrf_c20250101__20250930_zoLyrYmQaN1e" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance, percent"&gt;-21.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Income tax expense and effective tax rate&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxExpenseBenefit_iT_c20260101__20260930_zwsiuPWuV3Hj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expense and effective tax rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0753"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mtITEBzPrf_c20260101__20260930_zjL5q5cXRUB5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expense and effective tax rate, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0755"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IncomeTaxExpenseBenefit_iT_c20250101__20250930_zxSM6MMrYGwd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expense and effective tax rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0757"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mtITEBzPrf_c20250101__20250930_zA4b8qiYdES5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expense and effective tax rate, percent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0759"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000681"
      unitRef="USD">-591275</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact000683"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000685"
      unitRef="USD">-200352</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000687"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000705"
      unitRef="USD">-591275</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact000707"
      unitRef="Pure">-0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000709"
      unitRef="USD">-200352</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000711"
      unitRef="Pure">-0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000721"
      unitRef="USD">-1943927</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000723"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000725"
      unitRef="USD">-241918</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact000727"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000745"
      unitRef="USD">-1943927</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000747"
      unitRef="Pure">-0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000749"
      unitRef="USD">-241918</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact000751"
      unitRef="Pure">-0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000761">&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zsmxzYnkJDff" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income tax assets as of September 30, 2026 and December 31, 2025, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zNr6cCu3l72e"&gt;Schedule
of Deferred Income Tax Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20260930_zPMmgv8XCsie" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20251231_zkhL5LUXCGh2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGz12Q_zdiS3lkxX5J5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net operating losses carry forwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,961,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,017,359&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOtherTaxCarryforwards_iI_maDTAGz12Q_zCLPRAVjpgSg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,056&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0767"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGz12Q_maDTANzGAl_zQ3137UKUBT2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,963,342&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,017,359&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzGAl_zavHf2owuUUe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,963,342&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,017,359&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsNet_iNTI_di_mtDTANzGAl_z68GoZnFajvj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0775"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0776"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000763"
      unitRef="USD">2961286</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000764"
      unitRef="USD">1017359</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherTaxCarryforwards
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000766"
      unitRef="USD">2056</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000769"
      unitRef="USD">2963342</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000770"
      unitRef="USD">1017359</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000772"
      unitRef="USD">2963342</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000773"
      unitRef="USD">1017359</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2025-01-012025-12-31"
      decimals="0"
      id="Fact000778"
      unitRef="USD">1945983</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000780"
      unitRef="USD">1945983</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000782"
      unitRef="USD">14101362</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000784"
      unitRef="USD">4847550</us-gaap:OperatingLossCarryforwards>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000786">&lt;p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zTItmsPjY324" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_823_zylU0LJsORY4"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2025, Duraviva also assigned its office lease to the Company. The terms of the lease, including the original lease end date,
remained unchanged upon reassignment. The Company accounted for the lease under ASC 842 as an operating lease. Please refer to Note 4
Lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February and May 2025, the Company received two $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfLongTermDebt_c20250201__20250228_zXceb1hROfL2" title="Initial public offering"&gt;&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfLongTermDebt_c20250501__20250531_zqyPaveu0TO" title="Initial public offering"&gt;200,000&lt;/span&gt;&lt;/span&gt; loans from an existing shareholder to support ongoing costs related to its initial
public offering. The loans accrue simple interest at an annual rate of &lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20250228_zr3YmCCPr7x1" title="Interest rate"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20250531_z4lrkHMku3Me" title="Interest rate"&gt;4.34&lt;/span&gt;&lt;/span&gt;%, with both principal and interest due at maturity in &lt;span id="xdx_908_eus-gaap--DebtInstrumentMaturityDateDescription_dtM_c20250201__20250228_zZBfKGCbT5aj" title="Maturity date description"&gt;February&lt;/span&gt;
and &lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDateDescription_dtM_c20250501__20250531_zTRRdkJWKWTd" title="Maturity date description"&gt;May 2027&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2025, following the completion of the Company&#x2019;s IPO, the shareholder loans were fully repaid, including all accrued interest.
Total interest paid upon settlement amounted to $&lt;span id="xdx_906_eus-gaap--InterestPaid_pp2d_c20250901__20250930_z53DimZ04qsd" title="Interest paid"&gt;8,537.32&lt;/span&gt;. As a result of the repayment, there were no outstanding related-party loan
balances as of September 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="From2025-02-012025-02-28"
      decimals="0"
      id="Fact000788"
      unitRef="USD">200000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="From2025-05-012025-05-31"
      decimals="0"
      id="Fact000790"
      unitRef="USD">200000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-02-28"
      decimals="INF"
      id="Fact000792"
      unitRef="Pure">0.0434</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-05-31"
      decimals="INF"
      id="Fact000794"
      unitRef="Pure">0.0434</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="From2025-02-012025-02-28" id="Fact000796">February</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="From2025-05-012025-05-31" id="Fact000798">May 2027</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:InterestPaid
      contextRef="From2025-09-012025-09-30"
      decimals="2"
      id="Fact000800"
      unitRef="USD">8537.32</us-gaap:InterestPaid>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000802">&lt;p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_znjYycwAzpFb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82F_zgw3JprgqUca"&gt;Shareholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue &lt;span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20260930_z79gJgpmgiMd" title="Common stock, shares authorized"&gt;475,000,000&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260930_z3lgF40z8g86" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share. Each share entitles the holder to one
vote on matters submitted to stockholders and to receive dividends as and if declared by the Board of Directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company had &lt;span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20241231_zueqV3tQKOHg" title="Common stock, shares issued"&gt;&lt;span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zkYlh80Z8BW7" title="Common stock, shares outstanding"&gt;1,200,000&lt;/span&gt;&lt;/span&gt; shares of common stock issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year of 2025, the Company completed the following equity issuances in connection with its initial public offering and related activities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250827__20250827__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zR7BJQZRxHqd" title="Number of shares issued"&gt;187,500&lt;/span&gt; shares
    of common stock issued upon the closing of the IPO on August 27, 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250912__20250912__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zxP0DaRsLlA2" title="Number of shares issued"&gt;28,125&lt;/span&gt; additional shares
    of common stock issued on September 12, 2025 upon the underwriters&#x2019; exercise of their over-allotment option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250923__20250923__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zfjrXFkp8P74" title="Number of shares issued"&gt;1,416&lt;/span&gt; shares of common
    stock issued on September 23, 2025 to satisfy a previously recorded &#x201c;common stock to be issued&#x201d; balance (see &#x201c;Subscriptions
    Received &#x2013; Shares to be Issued&#x201d; below).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
these issuances, the Company had &lt;span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_z7y94uBfrkub" title="Common stock, shares outstanding"&gt;&lt;span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20251231_zMQ8Lmg2fxmd" title="Common stock, shares issued"&gt;1,417,041&lt;/span&gt;&lt;/span&gt; shares of its common stock issued and outstanding as of December 31, 2025, including an aggregate
of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcLFvLu1vLNf" title="Issuance of shares"&gt;217,041&lt;/span&gt; shares of common stock issued during the quarter ended September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 18, 2026, the Company issued an aggregate of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20260318__20260318__srt--TitleOfIndividualAxis__custom--Dr.HuijuanZhongMember_zFUbExva0g59" title="Number of shares issued for services"&gt;1,200&lt;/span&gt; shares of Common Stock to Dr. Huijuan Zhong as compensation for services. These
shares were issued in reliance on exemption from registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended,
as transactions by an issuer do not involve any public offering and are subject to contractual transfer restrictions until 12 months
following the Company&#x2019;s initial public offering. On July 27 and August 7, 2026, the Company issued &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_c20260727__20260727__srt--TitleOfIndividualAxis__custom--Dr.HuijuanZhongMember__us-gaap--PlanNameAxis__custom--TwentyTwentySixPlanMember_z6AkLAebTe49" title="Number of shares issued"&gt;70,000&lt;/span&gt; and &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesOther_c20260807__20260807__srt--TitleOfIndividualAxis__custom--Dr.HuijuanZhongMember__us-gaap--PlanNameAxis__custom--TwentyTwentySixPlanMember_z06gXch1Rcd7" title="Number of shares issued"&gt;80,000&lt;/span&gt; shares of
common stock, respectively to six nonemployee consultants under the 2026 Plan. On August 20, 2026, the Company effected a &lt;span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20260820__20260820_z6pQSaFRdls1" title="Reverse stock split"&gt;1-for-20&lt;/span&gt; Reverse
Stock Split of its common stock. Following these issuances and the effectiveness of the Reverse Stock Split, the Company had &lt;span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20260930_zyi0hXkgxpS5" title="Common stock, shares issued"&gt;&lt;span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20260930_z3ThDQVLMTT5" title="Common stock, shares outstanding"&gt;1,568,241&lt;/span&gt;&lt;/span&gt;
shares of common stock issued and outstanding as of September 30, 2026. For further information regarding the measurement and recognition
of the related stock-based compensation, see Note 8, Stock-Based Compensation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Subscriptions
Received &#x2013; Shares to be Issued&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2019, the Company received $&lt;span id="xdx_90D_eus-gaap--CommonStockSharesSubscriptions_iI_c20191231_zItNwKW9Tygg" title="Subscriptions received"&gt;200,000&lt;/span&gt; in cash from an existing investor for a subscription to common stock representing &lt;span id="xdx_902_ecustom--SubscriptionsReceivedPercentage_iI_pid_dp_uPure_c20191231_zjfys2CDXqOb" title="Subscriptions received percentage"&gt;0.1&lt;/span&gt;% of the Company&#x2019;s
then-anticipated total issued and outstanding shares upon completion of the IPO. This amount was recorded as &#x201c;common stock to be
issued&#x201d; within stockholders&#x2019; equity and remained outstanding as of December 31,2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the successful completion of the IPO, the Company issued &lt;span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250701__20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zqlgDenzEmNe" title="Number of shares issued"&gt;1,416&lt;/span&gt; shares of common stock during the quarter ended September 30, 2025 to
settle this subscription in full. As of September 30, 2026, there were &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_do_c20260101__20260930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zqVORI1SPhhk" title="Number of shares issued"&gt;no&lt;/span&gt; remaining shares or amounts recorded as &#x201c;common stock
to be issued.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Preferred
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue &lt;span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20260930_zGrglbsOyu1l" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231_zRk8mrQB3LWi" title="Preferred stock, shares authorized"&gt;25,000,000&lt;/span&gt;&lt;/span&gt; shares of preferred stock at $&lt;span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260930_zD9rgRCw6VO6" title="Preferred stock, par value"&gt;&lt;span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20251231_zfeIahdpUFgi" title="Preferred stock, par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt; per share. The Company&#x2019;s Board of Directors also
has the authority to issue additional preferred stock in one or more classes or series. On June 14, 2024, the Company&#x2019;s Board of
Directors approved the issuance of &lt;span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zgqtDIkZnlw9" title="Preferred stock, shares issued"&gt;1,000,000&lt;/span&gt; shares of Series A Super Voting Preferred Stock (&#x201c;Series A Preferred Stock&#x201d;)
at the par value of $&lt;span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMpJNI6pmAF5" title="Preferred stock, par value"&gt;0.0001&lt;/span&gt; per share. These shares grant the holders 40% of the total voting power of the Company&#x2019;s equity voting
stock. Holders of the Series A Preferred Stock do not possess any rights to dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_do_c20260101__20260930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zl3VBR75JdMc" title="Issuance of shares"&gt;No&lt;/span&gt;
shares of preferred stock were issued during the nine months ended September 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000804"
      unitRef="Shares">475000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000806"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000808"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000810"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-08-272025-08-27_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000812"
      unitRef="Shares">187500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-09-122025-09-12_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000814"
      unitRef="Shares">28125</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-09-232025-09-23_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000816"
      unitRef="Shares">1416</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000818"
      unitRef="Shares">1417041</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000820"
      unitRef="Shares">1417041</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000822"
      unitRef="Shares">217041</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2026-03-182026-03-18_custom_Dr.HuijuanZhongMember"
      decimals="INF"
      id="Fact000824"
      unitRef="Shares">1200</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2026-07-272026-07-27_custom_Dr.HuijuanZhongMember_custom_TwentyTwentySixPlanMember"
      decimals="INF"
      id="Fact000826"
      unitRef="Shares">70000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2026-08-072026-08-07_custom_Dr.HuijuanZhongMember_custom_TwentyTwentySixPlanMember"
      decimals="INF"
      id="Fact000828"
      unitRef="Shares">80000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2026-08-202026-08-20" id="Fact000830">1-for-20</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000832"
      unitRef="Shares">1568241</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000834"
      unitRef="Shares">1568241</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="Fact000836"
      unitRef="USD">200000</us-gaap:CommonStockSharesSubscriptions>
    <CURX:SubscriptionsReceivedPercentage
      contextRef="AsOf2019-12-31"
      decimals="INF"
      id="Fact000838"
      unitRef="Pure">0.001</CURX:SubscriptionsReceivedPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-012025-09-30_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000840"
      unitRef="Shares">1416</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-01-012026-09-30_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000842"
      unitRef="Shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000844"
      unitRef="Shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000846"
      unitRef="Shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000848"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000850"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-06-14_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000852"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-14_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000854"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-01-012026-09-30_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000856"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000858">&lt;p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zWZuZMPSVPB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
&lt;span id="xdx_824_zVh5PjvhFCyd"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2026
Equity Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 31, 2026, the Company&#x2019;s Board of Directors adopted the Curanex Pharmaceuticals Inc 2026 Equity Incentive Plan (the &#x201c;2026
Plan&#x201d;), which was approved by the Company&#x2019;s stockholders on June 11, 2026. The 2026 Plan permits the grant of stock options,
restricted stock, restricted stock units and other stock-based awards to employees, directors and consultants of the Company. An aggregate
of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260531__20260531__us-gaap--PlanNameAxis__custom--TwoThousandTwentySixEquityIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBwFbaXwkpo7" title="Common stock, shares"&gt;285,000&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260531__us-gaap--PlanNameAxis__custom--TwoThousandTwentySixEquityIncentivePlanMember_zuO4jg38fiJ" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share, are reserved and available for issuance under the 2026 Plan, representing
approximately &lt;span id="xdx_90D_ecustom--CommonStockIssuedAndOutstandingPercentage_pid_dp_uPure_c20260601__20260630__us-gaap--PlanNameAxis__custom--TwoThousandTwentySixEquityIncentivePlanMember_zACseSs5kN21" title="Common stock issued and outstanding percentage"&gt;20.1&lt;/span&gt;% of the shares of common stock issued and outstanding as of June 30, 2026. The 2026 Plan is administered by the Board
of Directors, or a committee designated by the Board, which determines the recipients, types, terms, vesting conditions and, where applicable,
exercise prices of awards. The number of shares reserved under the 2026 Plan is subject to proportionate adjustment in the event of a
stock split, reverse stock split, stock dividend, recapitalization or similar change in the Company&#x2019;s capitalization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 21, 2026, the Company filed a Registration Statement on Form S-8 with the Securities and Exchange Commission registering &lt;span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260721__us-gaap--PlanNameAxis__custom--TwoThousandTwentySixEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zX66FGtSajqf" title="Common stock reserved for issuance"&gt;150,000&lt;/span&gt;
of the &lt;span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260721__us-gaap--PlanNameAxis__custom--TwoThousandTwentySixEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zK6ZCMavSrzf" title="Common stock reserved for issuance"&gt;285,000&lt;/span&gt; shares of common stock reserved for issuance under the 2026 Plan, representing approximately &lt;span id="xdx_908_ecustom--CommonStockIssuedAndOutstandingPercentage_pid_dp_uPure_c20260721__20260721__us-gaap--PlanNameAxis__custom--TwoThousandTwentySixEquityIncentivePlanMember_zUpS15fN5lxj" title="Common stock issued and outstanding percentage"&gt;10.58&lt;/span&gt;% of the shares of common
stock issued and outstanding as of the date of filing. The Registration Statement became effective upon filing in accordance with Rule
462 under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). As of September 30, 2026, the remaining &lt;span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260930__us-gaap--PlanNameAxis__custom--TwoThousandTwentySixEquityIncentivePlanMember_zOiIUMA4Nub4" title="Common stock reserved for issuance"&gt;135,000&lt;/span&gt;
shares reserved under the 2026 Plan had not been registered. See Note 10 for the subsequent registration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the third quarter of 2026, the Company granted and issued &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20260701__20260930__us-gaap--PlanNameAxis__custom--TwoThousandTwentySixEquityIncentivePlanMember_zstg2ObECHK9" title="Shares granted"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_do_c20260930__us-gaap--PlanNameAxis__custom--TwoThousandTwentySixEquityIncentivePlanMember_z6MDyI21MHw9" title="Number of shares issued"&gt;150,000&lt;/span&gt;&lt;/span&gt; shares of common stock to six nonemployee consultants under the 2026
Plan. The grants comprised &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260726__20260726__us-gaap--PlanNameAxis__custom--TwoThousandTwentySixEquityIncentivePlanMember_zWCHAebJifId" title="Share grant"&gt;50,000&lt;/span&gt; shares effective July 26, 2026, &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260727__20260727__us-gaap--PlanNameAxis__custom--TwoThousandTwentySixEquityIncentivePlanMember_zopKcit5PqOj" title="Share grant"&gt;20,000&lt;/span&gt; shares effective July 27, 2026 and &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260807__20260807__us-gaap--PlanNameAxis__custom--TwoThousandTwentySixEquityIncentivePlanMember_zderY8mDDv5" title="Share grant"&gt;80,000&lt;/span&gt; shares effective August
7, 2026. The shares were issued in two batches of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20260727__20260727_z0ZDoSULeIVi" title="Share issued"&gt;70,000&lt;/span&gt; on July 27 and &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20260807__20260807_zi1HOgOiyfB8" title="Share issued"&gt;80,000&lt;/span&gt; on August 7, 2026. The awards were fully earned on the
respective effective dates, without time-based vesting, and are nonrefundable and nonforfeitable except for specified fraud, material
breach, misconduct or legal provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
grant-date fair value of these awards was $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20260701__20260930_zOkZDMCaSzci" title="Grant date fair value of share"&gt;573,100&lt;/span&gt;, based on split-adjusted closing share prices of $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260726__20260726_zXQqyqJT095d" title="Share price"&gt;3.758&lt;/span&gt;, $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260727__20260727_zdOBmEXGdiLa" title="Share price"&gt;3.66&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260807__20260807_zLmjbQN8sDg2" title="Share price"&gt;3.90&lt;/span&gt; for the July
26, July 27 and August 7 grants, respectively. The July 26 grant date was a non-trading day; the July 24 closing price was used. The
shares compensate two consultants for strategic business-development and licensing services over one-year terms and four consultants
for Australian clinical trial feasibility services over six-month terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized consulting expense of $&lt;span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20260701__20260930_zzY7xqIKePtl" title="Consulting expense"&gt;&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260930_zKfu6pMK1phc" title="Consulting expense"&gt;154,009&lt;/span&gt;&lt;/span&gt; for both the three and nine months ended September 30, 2026, comprising $&lt;span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260930__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpense_zdAgL6s5tBei" title="Consulting expense"&gt;34,491&lt;/span&gt; within
general and administrative expenses and $&lt;span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260930__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--ResearchAndDevelopmentExpense_zgJ0VKG4ZK0h" title="Consulting expense"&gt;119,518&lt;/span&gt; within research and development expenses. The remaining $&lt;span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260930__us-gaap--AwardTypeAxis__custom--PrepaidExpensesMember_zNUcWXF1mMB7" title="Consulting expense"&gt;419,091&lt;/span&gt; was recorded within
prepaid expenses, including $&lt;span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260930__us-gaap--AwardTypeAxis__custom--BusinessDevelopmentServicesMember_zMUeTNa8Ioo6" title="Consulting expense"&gt;153,409&lt;/span&gt; for business-development services and $&lt;span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260930__us-gaap--AwardTypeAxis__custom--ClinicalFeasibilityServicesMember_zhcDf1PzxCW9" title="Consulting expense"&gt;265,682&lt;/span&gt; for clinical-feasibility services. The costs are
recognized on a straight-line basis over the contractual service periods as services are received. All of the awards were vested; the
prepaid balance represents future services rather than unvested compensation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Other
Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 18, 2026, the Company issued an aggregate of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20260318__20260318__srt--TitleOfIndividualAxis__custom--Dr.HuijuanZhongMember_zFX4PQnQc0bj" title="Number of shars additional compensation"&gt;1,200&lt;/span&gt; shares of common stock to Dr. Huijuan Zhong as additional compensation pursuant
to an employment arrangement entered into in June 2024 (see Note 7, Shareholders&#x2019; Equity). Following the Company&#x2019;s initial
public offering, the Company issued the full &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260318__20260318__srt--TitleOfIndividualAxis__custom--Dr.HuijuanZhongMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQWz0RZjFN8a" title="Number of shares issued"&gt;1,200&lt;/span&gt; shares in a single issuance, and no further service-based forfeiture conditions remained
after issuance. All shares were vested upon issuance. The shares were valued at $&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_c20260318__srt--TitleOfIndividualAxis__custom--Dr.HuijuanZhongMember_zSpJBrkhcCKl" title="Per share"&gt;8.16&lt;/span&gt; per share, the closing price of the Company&#x2019;s
common stock on March 17, 2026 as reported on Nasdaq. The Company recognized stock-based compensation expense of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_dxL_c20260701__20260930__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpense_zqGt0aFfsLae" title="Stock based compensation::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;nil&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20260101__20260930__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpense_zVRXi2v1kVf5" title="Stock based compensation"&gt;9,792&lt;/span&gt; within
general and administrative expenses for the three and nine months ended September 30, 2026, respectively, and $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_dxL_c20250701__20250930__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpense_zBq3VLtD1Ioc" title="Stock based compensation::XDX::-"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_dxL_c20250101__20250930__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpense_zWlFpKTsm6lg" title="Stock based compensation::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0920"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0922"&gt;nil&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; for the three and
nine months ended September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-05-312026-05-31_custom_TwoThousandTwentySixEquityIncentivePlanMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000860"
      unitRef="Shares">285000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-05-31_custom_TwoThousandTwentySixEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000862"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <CURX:CommonStockIssuedAndOutstandingPercentage
      contextRef="From2026-06-012026-06-30_custom_TwoThousandTwentySixEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000864"
      unitRef="Pure">0.201</CURX:CommonStockIssuedAndOutstandingPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2026-07-21_custom_TwoThousandTwentySixEquityIncentivePlanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000866"
      unitRef="Shares">150000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2026-07-21_custom_TwoThousandTwentySixEquityIncentivePlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000868"
      unitRef="Shares">285000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <CURX:CommonStockIssuedAndOutstandingPercentage
      contextRef="From2026-07-212026-07-21_custom_TwoThousandTwentySixEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000870"
      unitRef="Pure">0.1058</CURX:CommonStockIssuedAndOutstandingPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2026-09-30_custom_TwoThousandTwentySixEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000872"
      unitRef="Shares">135000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2026-07-012026-09-30_custom_TwoThousandTwentySixEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000874"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2026-09-30_custom_TwoThousandTwentySixEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000876"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2026-07-262026-07-26_custom_TwoThousandTwentySixEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000878"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2026-07-272026-07-27_custom_TwoThousandTwentySixEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000880"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2026-08-072026-08-07_custom_TwoThousandTwentySixEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000882"
      unitRef="Shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2026-07-272026-07-27"
      decimals="INF"
      id="Fact000884"
      unitRef="Shares">70000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2026-08-072026-08-07"
      decimals="INF"
      id="Fact000886"
      unitRef="Shares">80000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000888"
      unitRef="USD">573100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2026-07-262026-07-26"
      decimals="INF"
      id="Fact000890"
      unitRef="USDPShares">3.758</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2026-07-272026-07-27"
      decimals="INF"
      id="Fact000892"
      unitRef="USDPShares">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2026-08-072026-08-07"
      decimals="INF"
      id="Fact000894"
      unitRef="USDPShares">3.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000896"
      unitRef="USD">154009</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000898"
      unitRef="USD">154009</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2026-01-012026-09-30_us-gaap_GeneralAndAdministrativeExpense"
      decimals="0"
      id="Fact000900"
      unitRef="USD">34491</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2026-01-012026-09-30_us-gaap_ResearchAndDevelopmentExpense"
      decimals="0"
      id="Fact000902"
      unitRef="USD">119518</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2026-01-012026-09-30_custom_PrepaidExpensesMember"
      decimals="0"
      id="Fact000904"
      unitRef="USD">419091</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2026-01-012026-09-30_custom_BusinessDevelopmentServicesMember"
      decimals="0"
      id="Fact000906"
      unitRef="USD">153409</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2026-01-012026-09-30_custom_ClinicalFeasibilityServicesMember"
      decimals="0"
      id="Fact000908"
      unitRef="USD">265682</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2026-03-182026-03-18_custom_Dr.HuijuanZhongMember"
      decimals="INF"
      id="Fact000910"
      unitRef="Shares">1200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-03-182026-03-18_custom_Dr.HuijuanZhongMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000912"
      unitRef="Shares">1200</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2026-03-18_custom_Dr.HuijuanZhongMember"
      decimals="INF"
      id="Fact000914"
      unitRef="USDPShares">8.16</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2026-01-012026-09-30_us-gaap_GeneralAndAdministrativeExpense"
      decimals="0"
      id="Fact000918"
      unitRef="USD">9792</us-gaap:ShareBasedCompensation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000924">&lt;p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zoGd9AW5c3m8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.
&lt;span id="xdx_821_zPacB5ARvL1d"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following two (2) putative securities class actions were commenced in New York state court relating to the Company&#x2019;s August 2025
IPO:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
first action (&#x201c;Action 1&#x201d;) was filed on July 23, 2026 in the Supreme Court of the State of New York, New York County (Index
No. 159271/2026), by Daymond Morales, et al. against the Company and its underwriters Dominari Securities LLC, Pacific Century Securities,
LLC, and Revere Securities LLC, as well as more than 20 other issuers, underwriters, and individual principals of the underwriters. The
complaint asserts claims under Sections 11 and 12(a)(2) of the Securities Act against the Company and other defendants, and claims under
Section 15 of the Securities Act against certain individuals associated with the underwriter defendants. The proposed class includes
persons who acquired the Company&#x2019;s securities in, or pursuant or traceable to the offering documents for, its August 2025 initial
public offering (the &#x201c;IPO&#x201d;) and allegedly suffered damages. The complaint alleges material misstatements and omissions in
the offering documents concerning risks of stock-price manipulation and deficiencies in underwriter due diligence, anti-money laundering
compliance, supervision, and business-communication monitoring. The complaint also makes general &#x201c;blanket&#x201d; allegations against
the defendants relating to market manipulation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
second action (&#x201c;Action 2&#x201d;) was filed on September 14, 2026 in the Supreme Court of the State of New York, New York County
(Index No. 655238/2026), by Robert Lovett, on behalf of himself and other purported class plaintiffs against the Company, its former
Chief Financial Officer, and directors, its independent auditor, and the IPO underwriters Dominari Securities LLC, Pacific Century Securities,
LLC, and Revere Securities LLC. The complaint asserts claims under Sections 11 and 12(a)(2) of the Securities Act against all named defendants
and Section 15 claims against the named individual defendants. The proposed class includes persons who acquired the Company&#x2019;s securities
in, or pursuant or traceable to the offering documents for, the IPO and allegedly suffered damages. The complaint alleges material misstatements
and omissions in those documents concerning risks of stock-price manipulation and deficiencies in underwriter due diligence, anti-money
laundering compliance, supervision, and business-communication monitoring.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The IPO offering documents referred to in both actions
consisted of the Company&#x2019;s registration statement on Form S-1, as amended, and related prospectuses under the Securities Act in
connection with its August 2025 IPO. Both complaints seek unspecified compensatory damages, interest, costs and expenses, including attorneys&#x2019;
and expert fees, rescission or rescissory damages, and equitable or other relief. Neither complaint asserts a fraud claim against the
Company. Both actions are at a preliminary stage, and the Company intends to defend them vigorously. The Company&#x2019;s deadline to respond
to Action 1 has been extended to January 27, 2027, and the deadline to respond to Action 2 has been extended to December 11, 2026.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000926">&lt;p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_znVgYhPmWv77" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.
&lt;span id="xdx_821_zVxPERF2z05i"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 19, 2026, the Company filed a registration statement on Form S-8 registering the remaining &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20261019__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zy3MJJOfwf7g" title="Number of common stock available"&gt;135,000&lt;/span&gt; shares of common stock available
under the 2026 Plan. The registration statement became effective upon filing. The Company has evaluated subsequent events through November
13, 2026.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2026-10-19_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000928"
      unitRef="Shares">135000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2026-07-012026-09-30" id="Fact000929">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2026-07-012026-09-30" id="Fact000930">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2026-07-012026-09-30" id="Fact000931">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2026-07-012026-09-30" id="Fact000932">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000102"
          xlink:label="Fact000102"
          xlink:type="locator"/>
        <link:footnote id="Footnote000140" xlink:label="Footnote000140" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Adjusted for the
<xhtml:span
  class="xdx_phnt_U3RhdGVtZW50IC0gQmFsYW5jZSBTaGVldHMgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20260101__20260930_zD213jnvl0g4"
  title="Reverse stock split">1-for-20</xhtml:span> reverse stock split (see Note 1 for details)</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000102"
          xlink:to="Footnote000140"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000104"
          xlink:label="Fact000104"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000104"
          xlink:to="Footnote000140"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000106"
          xlink:label="Fact000106"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000106"
          xlink:to="Footnote000140"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000108"
          xlink:label="Fact000108"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000108"
          xlink:to="Footnote000140"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000200"
          xlink:label="Fact000200"
          xlink:type="locator"/>
        <link:footnote id="Footnote000215" xlink:label="Footnote000215" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Adjusted for the
<xhtml:span
  class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zIChVbmF1ZGl0ZWQpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20260101__20260930_zz22eTJ4va4j"
  title="Reverse stock split">1-for-20</xhtml:span> reverse stock split (see Note 1 for details)</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000200"
          xlink:to="Footnote000215"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000202"
          xlink:label="Fact000202"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000202"
          xlink:to="Footnote000215"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000204"
          xlink:label="Fact000204"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000204"
          xlink:to="Footnote000215"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000206"
          xlink:label="Fact000206"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000206"
          xlink:to="Footnote000215"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000208"
          xlink:label="Fact000208"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000208"
          xlink:to="Footnote000215"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000210"
          xlink:label="Fact000210"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000210"
          xlink:to="Footnote000215"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000212"
          xlink:label="Fact000212"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000212"
          xlink:to="Footnote000215"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000214"
          xlink:label="Fact000214"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000214"
          xlink:to="Footnote000215"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000226"
          xlink:label="Fact000226"
          xlink:type="locator"/>
        <link:footnote id="Footnote000375" xlink:label="Footnote000375" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Adjusted for the
<xhtml:span
  class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50IG9mIENoYW5nZXMgaW4gU2hhcmVob2xkZXJzJyBFcXVpdHkgKFVuYXVkaXRlZCkgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20260101__20260930_zO1UatC7E8Zi"
  title="Reverse stock split">1-for-20</xhtml:span> reverse stock split (see Note 1 for details)</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000226"
          xlink:to="Footnote000375"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000244"
          xlink:label="Fact000244"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000244"
          xlink:to="Footnote000375"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000262"
          xlink:label="Fact000262"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000262"
          xlink:to="Footnote000375"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000273"
          xlink:label="Fact000273"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000273"
          xlink:to="Footnote000375"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000289"
          xlink:label="Fact000289"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000289"
          xlink:to="Footnote000375"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000300"
          xlink:label="Fact000300"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000300"
          xlink:to="Footnote000375"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000311"
          xlink:label="Fact000311"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000311"
          xlink:to="Footnote000375"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000327"
          xlink:label="Fact000327"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000327"
          xlink:to="Footnote000375"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000345"
          xlink:label="Fact000345"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000345"
          xlink:to="Footnote000375"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000356"
          xlink:label="Fact000356"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000356"
          xlink:to="Footnote000375"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000372"
          xlink:label="Fact000372"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000372"
          xlink:to="Footnote000375"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
